Clinical Study Protocol  
 
Protocol Title:  A Phase 1 / 2, Randomized, Double -blind, Placebo-
controlled, Multi- center Clinical Trial of Allogeneic Bone 
Marrow-derived Human Mesenchymal Stem Cells for the 
Treatment of Acute Respi[INVESTIGATOR_347942]: Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells (h MSCs) 
Protocol 
Number:  UCSF-hMSC-ARDS-P1P2-06 
IND Number:  [ZIP_CODE] 
Sponsor-
Investigator:  Michael A. Matthay, MD  
University of [LOCATION_004], San Francisco  
 
 
Signature:  _________________________________________ 
 
 
Original Date:  
 
   17 February 2015  
 
 
Confidentiality Statement  
 
This document is confidential and is to be distributed for review only to investigators, potential 
investigators, consultants, study staff, and applicable independent ethics committees or 
institutional review boards. The consents of this document shall not be disclosed to others without 
written authorization from NHLBI, unless it is necessary to obtain informed consent from 
potential study participants. 
 
 
PROTOCOL Approval  
Michael A Matthay, MD   Page ii 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
 
Protocol:  
 
UCSF-hMSC-ARDS-P1P2-04 
 Version/Date:  
 
February 17, 2015 
IND: [number] 
 
[ZIP_CODE] Protocol Chair:  
 
Michael A. Matthay, MD  
 
Short Title:   Mesenchymal Stem Cells  For Acute Respi[INVESTIGATOR_39053] 
 
 
 
I have read protocol UCSF-hMSC-ARDS-P1P2-06, and I approve it . As the principal 
investigator, I agree to conduct this protocol according to good clinical practices, which are 
delineated in the International Conference on Harmonization (ICH) of Technical Requirements 
for Registration of Pharmaceuticals for Human Use “Guidance  for Industry: E6 Good Clinical 
Practice Consolidated Guidance” (May 1996), and according to the criteria specified in this 
protocol. 
 
Print Name [CONTACT_789] [or Protocol Chair]:  
 
______________________________________________________ 
 
Signature:______________________________________________    
 Date:__________________________________________________ 
 
 
 
   
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page iii 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Protocol Synopsis  
Name [CONTACT_790] – 
Investigator Michael A. Matthay, MD 
University of [LOCATION_004], San Francisco 
Investigational Product  Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells  (hMSCs) 
Protocol Number:  UCSF-hMSC-A RDS-P1P2-06 
Title: A Phase 1/ 2, Randomized, Double-blind, Placebo-
controlled, Multi- center Clinical Trial of Allogeneic Bone 
Marrow-Derived Human Mesenchymal Stem Cells for the 
Treatment of Acute Respi[INVESTIGATOR_347943] [ADDRESS_432303]  Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells ( hMSCs) 
IND Number  [ZIP_CODE] 
Participating Sites  Multi-center Intensive Care Unit study sites 
Study Objective  To assess the safety and efficacy of hMSCs in critically ill 
patients with Acute Respi[INVESTIGATOR_39053]  (ARDS) 
Accrual Objective  Phase 1: 9 patients  receiving hMSCs (3 patients per dose)  
Phase 2: 60 patients (40 patients receiving hMSCs and 20 
patients receiving placebo)   
Study Design  Phase 1: Open label, dose escalation, multi- center 
Phase 2: Randomized, double-blind, placebo-controlled, multi-center  
Subjects with ARDS will receive a single infusion of hMSCs 
or placebo . 
Study Product, Dose, Route, 
Regimen  
 The cellular product is  cryopreserved for long-term storage. 
The cryopreserved hMSCs are formulated DMSO (10%), 
human serum albumin (5 %) and Plasma-Lyte A (30%).  
Immediately prior to administration, the product is thawed, 
washed, and resuspended in Plasma-Lyte A, a clinical -grade 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page iv 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Name [CONTACT_790] – 
Investigator Michael A. Matthay, MD 
University of [LOCATION_004], San Francisco 
Investigational Product  Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells  (hMSCs) 
infusible solution for intravenous admi nistration .  
Placebo: Plasma-Lyte A 
 
For both Phase 1 and Phase 2, each dose of the hMSCs  or 
placebo will be administered intravenously over approximately 60-80 minutes. All patients will receive one 
dose.  
Phase 1: Dose Escalation  
1 x 10
6 cells/kg (n=3), 5 x 106 cells/kg (n=3) and  
10 x 106 cells/kg (n=3)  
Phase 2: 
10 x 106 cells/kg (n= 40); placebo (n=20) 
Primary Phase 1 and 2 
Endpoint :  Safety: Tolerability of the  hMSCs, defined based on the 
incidence of pre-specified infusion associated events and of 
unexpected severe adverse events in ARDS patients treated with hMSCs.  
Secondary Phase 2 
Endpoint s:  Efficacy:  
Respi[INVESTIGATOR_347944]: Oxygenation index, PaO 2/FiO2 ratio 
and  acute lung injury score   
Systemic endpoints: Brussels organ failure- free days, mean 
daily Sequential Organ Failure Assessment  (SOFA) score, 
vasopressor- free, ventilator- free, intensive care unit (IC U) 
free days, as well as 60 day all -cause mort ality 
Biomarkers : Change in levels of plasma biomarkers of lung 
epi[INVESTIGATOR_196648] ( Receptor for Advanced Glycation 
Endproducts, RAGE), pro - and anti- inflammatory markers 
(interleukin -6, interleukin-8, interleukin-10 and interleukin-
1Ra), endothelial injury (plasma v on Willebrand factor 
[vWF], ang iopoietin-2 [Ang-2]), markers of change in other 
organ function (creatinine) and markers that reflect the paracrine activity of the administered hMSCs (angiopoietin-
1 [Ang-1] and keratinocyte growth factor [K GF]) as well as 
lung protein permeability ( bronchoalveolar lavage [BAL] 
protein) at day 2. 
Inclusion Criteria  Patients will be eligible for inclusion if they meet all of the below criteria. Criteria [ADDRESS_432304] all be present within a 24-
hour time period and at the time of enrollment: 
Acute onset (defined below) of: 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page v 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Name [CONTACT_790] – 
Investigator Michael A. Matthay, MD 
University of [LOCATION_004], San Francisco 
Investigational Product  Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells  (hMSCs) 
1. A need for positive pressure ventilation by [CONTACT_348047] a PaO 2/FiO2 ratio < 
[ADDRESS_432305] pressure (PEEP) . A patient may b e included if the 
PaO2/FiO2 ratio < 200 with < 8 cm H 2O PEEP if there is 
a contraindication to increased PEEP: evidence of 
barotrauma.   
2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph  
3. No clinical evidence of left atrial hypertension for 
bilateral pulmonary infiltrates.  
 
• Acute onset  is defined as follows:  The duration of the 
hypoxemia criterion (#1) and the chest radiograph 
criterion (#2) must be < 28 days at the time of 
randomization  
• Infiltrates considered “consistent with pulmonary edema” 
include any infiltrates not fully explained by [CONTACT_27225], 
atelectasis, or effusion or opacities known to be chronic (greater than 28 days). Vascular redistribution, indistinct vessels, and indistinct heart borders alone are not considered “consistent with pulmonary edema” and thus would not count as qualifying opacities for this study. 
• If a patient meets the first two inclusion criteria but has a 
PAOP (Pulmonary Arterial Occlusion Pressure, also known as the Pulmonary Arterial Wedge Pressure) 
greater than [ADDRESS_432306] for more than 12 hours after the PAOP has declined to ≤ [ADDRESS_432307] meeting ARDS criteria 
per the Berlin definition of ARDS 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page vi 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Name [CONTACT_790] – 
Investigator Michael A. Matthay, MD 
University of [LOCATION_004], San Francisco 
Investigational Product  Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells  (hMSCs) 
3. Pregnant or breast -feeding  
4. Prisoner 
5. Presence of any active malignancy  (other than non-
melanoma skin cancer)  that required treatment within the 
last 2 years  
6. Any other irreversible disease or condition for which 6-
month mortality is estimated to be greater  than 50%  
7. Moderate to severe liver failure (Childs -Pugh Score > 
12)  
8. Severe chronic respi[INVESTIGATOR_347945] a PaCO 2 > 50 
mm Hg or the use of home oxygen 
9. Patient, surrogate, or physician not committed to full 
support (e xception: a patient will not be excluded if 
he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)  
10. Major trauma in the prior 5 days 
11. Lung transplant patient 
12. No consent/inability to obtain consent 
13. Moribund patient not expected to survive [ADDRESS_432308] 3 months  
16. No arterial line/no intent to place an arterial line  
17. No intent/unwillingness to follow lung protective ventilation strategy or fluid man agement protocol 
18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HF OV) 
 
Statistical Consideration  The primary safety analysis will be descriptive and will 
focus, as described above, on the incidence of pre-specified 
infusion associated events  and of unexpected severe adverse 
events in ARDS patients treated with hMSCs.  
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 1 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Table of Contents  
 
PROTOCOL SYNOPSIS  ............................................................................................................................. III 
TABLE OF CONTENTS  ............................................................................................................................... 1 
GLOSSARY OF ABBREVIA TIONS ............................................................................................................. 4 
1 BACKGROUND  ................................................................................................................................... 5 
1.1 SUMMARY  .......................................................................................................................................... 5 
1.2 SCIENTIFIC RATIONALE  ....................................................................................................................... 5 
1.2.1  Significance of this work to Acute Lung Injury/Acute Respi[INVESTIGATOR_39053] ........... 5 
1.3 BACKGROUND RELEVANT TO MECHANISM OF ACTION OF MESENCHYMAL STEM CELLS IN ALI/ARDS  ..... 6 
1.3.1  Engraftment and Trans -differentiation  ..................................................................................... 6 
1.3.2  Immunomodulatory & Anti -inflammatory Effects  ..................................................................... [ADDRESS_432309] AND DOSE SELECTION  ................................. 11 
1.6 CLINICAL EXPERIENCE  ...................................................................................................................... 12 
1.7 POTENTIAL BENEFITS AND RISKS TO HUMAN PARTICIPANTS  ............................................................... 14 
1.7.1  Potential Benefits  .................................................................................................................. 14 
1.7.2  Potential Risks  ....................................................................................................................... 15 
1.8 STUDY RATIONALE  ........................................................................................................................... 16 
2 STUDY OBJECTIVES  ....................................................................................................................... 16 
2.1 PRIMARY OBJECTIVE  ........................................................................................................................ 16 
2.2 SECONDARY OBJECTIVE  ................................................................................................................... 16 
3 STUDY DESIGN  ................................................................................................................................. 17 
3.1 PHASE 1 STUDY DESIGN  ................................................................................................................... 17 
3.2 PHASE 2 STUDY DESIGN  ................................................................................................................... 17 
4 ENDPOINTS ....................................................................................................................................... 18 
4.1 PRIMARY STUDY ENDPOINT : PHASE 1 AND PHASE 2........................................................................... 18 
4.2 SECONDARY ENDPOINTS : PHASE 2 ................................................................................................... 19 
5 STUDY POPULATION AND ENROLLMENT  .................................................................................... 20 
5.1 NUMBER /SOURCE /SCREENING  .......................................................................................................... [ADDRESS_432310] RECRUITMENT AND INFORMED CONSENT  ............................................................................ 23 
5.6 RANDOMIZATION  ............................................................................................................................... 23 
5.7 EARLY WITHDRAWAL OF SUBJECTS  ................................................................................................... 24 
5.7.1  When and How to Withdraw Subjects  ................................................................................... 24 
5.7.2  Data Collection and Follow -up for Withdrawn Subjects  ........................................................ 24 
6 STUDY DRUG  .................................................................................................................................... 24 
6.1 DESCRIPTION  ................................................................................................................................... 24 
6.2 TREATMENT REGIMEN  ...................................................................................................................... 24 
Date:  February 17, [ADDRESS_432311]-HOSPI[INVESTIGATOR_347946] -UP ................................................................................................. 30 
8 DATA COLLECTION ......................................................................................................................... 31 
8.1 MEDICAL HISTORY  ............................................................................................................................ 31 
8.2 BASELINE ASSESSMENTS  .................................................................................................................. 31 
8.2.1  To Be Collected From Patient Charts .................................................................................... 31 
8.3 ASSESSMENT AFTER ENROLLMENT : DETERMINATION OF STABLE BASELINE FOR H MSC S 
ADMINISTRATION , MONITORING DURING AND AFTER INFUSION PROTOCOL  ................................................... 32 
8.4 ASSESSMENT AFTER ENROLLMENT : REFERENCE MEASUREMENTS  ...................................................... 32 
8.4.1  Reference Measurements (to be collected from patient charts)  ........................................... [ADDRESS_432312] POPULATION (S) FOR ANALYSIS  ........................................................................................... 35 
10 SAFETY AND ADVERSE EVENTS ................................................................................................... 36 
10.1  DEFINITIONS ..................................................................................................................................... 36 
10.2  RECORDING OF ADVERSE EVENTS  .................................................................................................... 37 
10.3  REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  ..................................... 38 
10.3.1  Investigators’ Reporting Requirements to the Sponsor  .................................................... 38 
10.3.2  Sponsor Reporting: Notifying the FDA  .............................................................................. 38 
10.3.3  Sponsor Reporting:  Notifying the DSMB  ......................................................................... [ADDRESS_432313] KEEPI[INVESTIGATOR_1645]  ................................................................................... 42 
Date:  February 17, [ADDRESS_432314] OF REFERENCES  .................................................................................................................... 44 
17 APPENDICES  .................................................................................................................................... 50 
APPENDIX A: TIME-EVENTS SCHEDULE  ...................................................................................................... 51 
APPENDIX B: LUNG INJURY SCORE  ............................................................................................................ 52 
APPENDIX C: DE-IDENTIFIED DATA ELEMENTS FOR SCREENED , NON-ENROLLED SUBJECTS  .......................... 53 
APPENDIX D: ALCOHOL USE DISORDER IDENTIFICATION TEST (AUDIT)  ....................................................... 54 
 54 
APPENDIX E: VENTILATOR MANAGEMENT  ................................................................................................... 55 
APPENDIX F: CLINICAL CELL WASH PROTOCOL  .......................................................................................... 59 
APPENDIX G: HUMAN MESENCHYMAL STEM CELL INFUSION PROCEDURE  .................................................... 64 
APPENDIX H: GUIDELINES FOR SYMPTOM MANAGEMENT DURING H MSC S INFUSION  .................................... [ADDRESS_432315] INFUSION PROTOCOL  ........................................ 72 
APPENDIX K. BAROTRAUMA  ....................................................................................................................... 77 
 
  
Date:  February 17, [ADDRESS_432316] 
IV Intravenous(ly) 
LOCF Last Observation Carried Forward  
MSCs Mesenchymal Stem Cells  
PAOP Pulmonary artery occlusion pressure 
PEEP Positive end- expi[INVESTIGATOR_347947]:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 5 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
1 BACKGROUND  
1.1 Summary  
We hypothesize that A llogeneic Bone Marrow -derived Human Mesenchymal Stem C ells 
(referred to hereafter as hMSCs) administered to patients with the Acute Respi[INVESTIGATOR_129639] (ARDS) will be safe and effective. A combined Phase [ADDRESS_432317] th e safety and efficacy based on potential treatment of the 
major abnormalities that underlie ARDS, including altered lung endothelial and epi[INVESTIGATOR_347948].  
1.2 Scientific Rationale  
1.2.1 Significance of this work to  Acute Lung Injury/Acute Respi[INVESTIGATOR_347949]  
(ALI) and  its more severe form, ARDS, in the last decade, despi[INVESTIGATOR_347950] ( 1-3). Current treatment remains primarily supportive with lung -protective 
ventilation and a fluid conservative strategy (4, 5). Pharmacologic therapi[INVESTIGATOR_347951]. At present, the mortality rate of severe ARDS remains unacceptably high, in the range of 30 -40% (6, 7). Therefore, innovative therapi[INVESTIGATOR_66039].  
 Cell-based therapy with mesenchymal stem cells for the treatment of ALI/ARDS is attractive as 
a potential new therapy . Mesenchymal stem cells (MSCs) are multi- potent and have the ability to 
secrete multiple paracrine factors such as growth factors that can enhance tissue repair, anti -
inflammatory cytokines and also anti microbial peptides. All of thes e paracrine factors can 
potentially treat the major abnormalities that underlie ALI, including impaired alveolar fluid clearance, altered lung endothelial and epi[INVESTIGATOR_322483], dysregulated inflammation and ongoing inf ection.  
 MSCs, also called marrow stromal stem cells, were first discovered in 1968 by [CONTACT_348048] (8) 
who found bone marrow stromal cells that were adherent, clonogenic, and fibroblastic in appearance. Adult mesenchymal stem cells  can be isolated from a variety of human tissues, 
including bone marrow, adipose tissue, liver, tendons, synovial membrane, amniotic fluid, placenta, umbilical cord blood, and teeth. MSCs are presumed to reside near the sinusoids and 
function as support ce lls for hematopoietic stem cells (HSC) . Although MSCs comprise less than 
0.1% of all bone marrow cells, they can be isolated from whole bone marrow aspi[INVESTIGATOR_347952] . Currently, there are no cell surface mark ers 
specific to MSCs. Consequently, in 2006, the International Society of Cellular Therapy defined 
MSCs by [CONTACT_32616]:  
(1) MSCs must be adherent to plastic under standard tissue culture conditions 
(2) MSCs must express certain cell surface markers such as CD105, CD90, and CD73, but must not express other markers including CD45, CD34, CD14, or CD11b; and  
(3) MSCs must have the capacity to differentiate into mesenchymal lineages including osteoblasts, adipocytes, and chrondoblasts under in vitro  conditions ( 9).  
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 6 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
 
Use of these cells for therapeutic purposes in a variety of diseases has attracted considerable attention due to their low immunogenicity, their immunomodulatory effects, and their ability to secrete endothelial and epi[INVESTIGATOR_347953] .  
1.3 Background R elevant to Mechanism of Action of Mesenchymal Stem 
Cells in ALI/ARDS  
Several mechanisms of action have been established in the literature for the therapeutic effect of MSCs in lung injury models.  
1.3.[ADDRESS_432318] in MSCs therapy stemmed from the multi- potent properties of the 
cells. Krause et al (10) found that a single bone marrow -derived cell could give rise to cells of 
multiple different organs including the lung . They reported up to 20% engraftment of bone 
marrow-derived cells in the lung, including epi[INVESTIGATOR_1663], from a single hematopoietic 
precursor . Kotton et al (11) reported that plate -adherent cultured bone marrow cells, when given 
intravenously in wild- type mice following bleomycin -induced lung injury, engrafted into the 
recipi[INVESTIGATOR_347954] a morphological and molecular phenotype of alveolar type I pneumocytes. This report gave rise to intensive investigation into the possibility that MSCs may 
be able to regenerate the lung epi[INVESTIGATOR_241117]/or endothelium (10-14). However, these results 
were questioned by [CONTACT_111306], who observed only engraftment of leukocyte lineages (15), 
or low engraftment rates in lung injury models with observed rates of < 1% (16-19). Despi[INVESTIGATOR_347955]- potent properties, engraftment in the lung does not appear to play a 
major beneficial role. The beneficial effect of MSCs appears to derive more from their capacity 
to secrete paracrine soluble factors that modulate immune responses as well as alter the responses of endothelium or epi[INVESTIGATOR_347956] (20-27). 
There may also be important cell -contact [CONTACT_348049][INVESTIGATOR_347957] ( 28). 
1.3.2 Immunomodulatory & Anti -inflammatory Effects  
A major characteristic of MSCs has been the immunomodulatory properties of the cells . Multiple 
studies have demonstrated that MSCs possess  potent immunosuppressive effects by [CONTACT_348050] (22, 23, 29, 30). This immunosuppression 
has been shown to be mediated by [CONTACT_320654] -dependent and -independent mechanisms through 
the release o f soluble factors . The list of candidate mediators released or induced by [CONTACT_348051] -β, PGE 2, IDO, TSG, IL -10 and IL -1ra among others. In a model of sepsis 
following cecal ligation and puncture (CLP) in mice, Nemeth et al. (20) found that MSCs, 
activated by [CONTACT_348052]-α, secreted prostaglandin E 2, which reprogrammed alveolar 
macrophages to secrete IL -10. The beneficial effect of MSCs on mortality and improved organ 
function following sepsis (CLP ) was eliminated by [CONTACT_348053] -10 or the IL -10 receptor, suggesting a beneficial role for IL -10 in these 
experiments; IL -10 is a cytokine secreted predominantly by [CONTACT_348054]- regulates the 
expression  of Th1 cytokines, MHC class II antigens, and co- stimulatory molecules on 
macrophages. IL-10 has also been reported to inhibit the rolling, adhesion and transepi[INVESTIGATOR_347958] (31). In co-culture experiments, cell contact [CONTACT_348055]:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 7 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
macrophages was required to stimulate IL -10 production following LPS stimulation; MSCs 
separated by a Transwell plate or MSCs conditioned medium could not induce IL -10 production 
(20). In a model of ALI following intratracheal E. coli endotoxin in mice, we (32) found that 
intra-pulmonary MSCs improved survival and lung injury in association with a decrease in MIP -
2 and TNF-α levels in the bronchoalveolar lavage fluid (BAL) and elevated levels of IL -10 in 
both the plasma and BAL fluids . In bleomycin- induced lung injury and fibrosi s in mice, Ortiz et 
al (33) found that MSCs decreased subsequent lung collagen accumulation, fibrosis and levels of 
matrix metalloproteinases in part by [CONTACT_8668] -1ra secretion; IL -1ra is a cytokine that competitively 
competes with  IL-1β for IL-1 receptor binding . IL-1β is one of the major inflammatory 
cytokines in pulmonary edema fluid in patients with ALI/ARDS (34). These results confirmed 
the anti-inflammatory effects of MSCs in multiple lung injury experiments in mice (16, 17, 35-
37). 
 Despi[INVESTIGATOR_347959], recent literature described a dual role for MSCs as an immunostimulatory cell as well (38). As explained above, some studies 
have reported that MSCs can upregulate expression of MHC II when exposed to low levels of inflammation and function as antigen presenting cells stimulating the adaptive immune system (39, 40). Recent evidence has also shown that MSCs can secrete IL -6 and induce production of 
IgG by B lymphocytes in an in vitro setting (41). In addition, MSCs can prevent neutrophil 
apoptosis and degranulation in culture without inhibiting their phagocytic or chemotactic capabilities (42). Thus, these studies have demonstrated that MSCs have more complex effects 
on the immune system than their classical role as immune suppressor cells . Understanding the 
mechanisms responsible for these apparently paradoxical roles that MSCs play in the immune response is important in developi[INVESTIGATOR_347960]- based therapy for clinical use.  
1.3.[ADDRESS_432319] common 
etiologies of ARDS  (1). Given the preponderance of literature that describes the 
immunosuppressive effect of MSCs, there might be concern that this effect may impede the host’s ability to clear an infection. However, new work de scribes a dual role for MSCs in 
regulating the immune system and their immunostimulatory effects . Further, a recent report has 
demonstrated  a protective effect of systemically administered MSCs in a mouse model of 
bacterial sepsis (20) as well as data from our own group at UCSF that MSCs are associated with 
a reduction in the number of live bacteria i n E. coli pneumonia in mice . The anti-microbial effect 
with mouse MSCs depended in part  on the release of lipocalin -2, a well know n anti-microbial 
peptide, from both the MSCs themselves and alveolar macrophages  (43). Also, we have found 
that the release of LL -37 by [CONTACT_348056] E. coli pneumonia 
in mice (44). In recent work with gram negative peritoneal sepsis in mice, our group has also 
found that intravenous hMSCs improve survival and reduce the number of bacteria in the blood 
when given after the peritoneal sepsis was established  (45). Another study reported better 
survival following treatment with MSCs in a cecal- ligation model of peritonitis in mice (46). 
Thus, based on preclinical evidence, treatment with MSCs has been associated with a reduction 
in the number of bacteria in mouse models of peritoneal sepsis and pneumonia.  
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 8 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
1.3.4 Secretion of Paracrine  Soluble Factors that Enhance Alveolar Fluid Clearance and 
the Resolution of Alveolar Edema  
Impaired alveolar fluid clearance (AFC, i.e. , delayed resolution of pulmonary edema) is 
common in patients with ALI/ARDS . The level of AFC impairment has significan t 
prognostic value in determining morbidity and mortality (47, 48). Several experimental 
studies have investigated  the mechanisms that reduce AFC i n ALI, and several pathways 
have been implicated (49, 50). In the alveolar environment, basal AFC is determined 
predominately by [CONTACT_348057] -sensitive and insensitive sodium channels and the activity of the 
Na-K ATPase (49, 51-54). Several stimuli can upregulate AFC including beta -adrenergic 
agonists via cAMP -dependent mechanisms (49, 50). In the mouse and human lung, cAMP -
dependent alveolar epi[INVESTIGATOR_347961], especially in 
mediating β-adrenergic receptor -driven alveolar epi[INVESTIGATOR_347962] (55-57). 
 
We and other investigators have reported that pulmonary  edema fluid contained high levels 
of several pro -inflammatory cytokines, including IL -1β, IL-8, TNF-α and TGF-β1 (58-60). 
Several of these pro -inflammatory cytokines have been studied in experimental fluid 
transport experiments . For example, TNF-α decreased the expression of ENaC ( α-, β-, γ-
subunits) mRNAs and protein levels , as well as the amiloride -sensitive current and ouabain -
sensitive Rb+ uptake in rat alveolar epi[INVESTIGATOR_1663] (61). Similarly, IL -1β decreased 
dexamethasone-induced αENaC mRNA and protein levels , and the amiloride -sensitive 
fraction of the transepi[INVESTIGATOR_347963] 
(62). More recently, we reported that TGF -β1 decreased the amiloride- sensitive fraction of 
Na+ uptake and fluid transport across monolayers of rat and human type II cells as well as 
αENaC mRNA and protein expression (63). In chronic inflammation associated with nasal 
polyposis, TGF -β1 down-regulated CFTR mRNA and protein expression as well as the 
cAMP-dependent current in human nasal epi[INVESTIGATOR_1663] ( 64).  
 
MSCs are known to produce several epi[INVESTIGATOR_347964], specifically keratinocyte growth factor (KGF), the seventh member of the fibroblast growth factor family . We have been 
particularly interested in KGF because of work from our group, as well as from other 
investigators who have reported that KGF can reduce lung injury in small animal models of pulmonary edema and lung injury . Recombinant KGF pretreatment reduced mortality following 
intra-tracheal instillation of hydrochloric acid (65, 66), bleomycin (67, 68), hyperoxia (69, 70) 
and Pseudomonas aeruginosa ( 71). In rat lungs, KGF improved alveolar fluid transport in part by 
[CONTACT_25764]-regulating αENaC gene expression ( 72) and Na- KATPase activity (73).  
 In the ex vivo perfused human lung, the intra -bronchial instillation of hMSCs one hour following 
endotoxin- induced lung injury restored AFC in part by [CONTACT_348058] (74). Several 
properties of KGF could explain the therapeutic effect of hMSCs on restoring AFC, including alveolar epi[INVESTIGATOR_347965], surfactant production (75), anti-
apo
ptotic effects (76) and increased transcription and/or translation of the major sodium and 
chloride transport proteins (72, 73). Because the effect of MSCs in E. coli endotoxin-induced 
lung injury in the ex vivo perfused human lung model occurred over a 3 -hour time period, the 
therapeutic benefit of KGF in these experiments is le ss likely explained by [CONTACT_348059] . Alternatively, an increase in vectorial fluid transport across 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 9 
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
the alveolar epi[INVESTIGATOR_347966] e (77, 78).  
 We have an established collaboration with the NIH sponsored Production Assistance for Cellular 
Therapy (PACT) Group in the University of Minnesota (Principal Investigator: [INVESTIGATOR_347967], 
MD) for the production of cGMP clinical gra de, cryopreserved hMSCs. In additional 
experiments in the ex vivo perfused human lung, we have found that these hMSCs were effective 
in both endotoxin and live E. coli lung injury models in restoring the rate of AFC over 6 hours 
whether given intravenous ly or intratracheal ly (Lee, JW et al, Manuscript submitted).  
 We also have recently completed experiments with hMSCs in sheep with ALI over [ADDRESS_432320] also completed IND-enabling safety studies in 
rats with ALI. 
1.3.5 Secretion of Paracrine Soluble Factors that Improve Lung Endothelial and 
Epi[INVESTIGATOR_347968] . The 
integrity of the lung microvascular endothelium is essential to prevent the influx of protein- rich 
fluid from the plasma as well as inflammatory cells which may further aggravate the ability of 
the lung epi[INVESTIGATOR_347969] . Several paracrine soluble factors, such as 
angiopoietin- 1 (Ang-1) and KGF, a re potentially important in predicating these effects . Ang-1, a 
ligand for the endothelial Tie2 receptor, is a known endothelial survival (79) and vascular 
stabilization factor that reduces endothelial permeability and inhibits leukocyte -endothelium 
interactions by [CONTACT_348060] (80-83). 
Regular MSCs or MSCs (used as a vehicle for gene delivery) transfected with the human Ang-1 
gene, reduced both pulmonary vascular endothelial injury and the recruitment of inflammatory 
cells into the lungs of mice injured by [CONTACT_162267] -induced lung injury (35, 37, 84). In a study by [CONTACT_348061]. (35), the transfection of Ang-[ADDRESS_432321] on lung epi[INVESTIGATOR_347970] ( 85). 
 KGF is one of  several epi[INVESTIGATOR_018] -specific g rowth factors produced by [CONTACT_348062]. In models of acute 
permeability edema such as α-naphthylthiourea ( 86), P. aeruginosa ( 71) or ventilator -induced 
lung injury (87), KGF reduced lung edema and bronchoalveolar lavage protein levels. Cultured 
allogeneic hMSCs produced substantial quantities of  KGF. The role of KGF is intriguing given 
the previous studies of  ALI in animal models . A recent study by [CONTACT_348063]. reported that 
fibroblast growth factors (FGF), FGF2, FGF4 and FGF8 are specific for bot h FGF receptors 
1IIIc and 3IIIc  and are responsible for the maintenance of endothelial barrier homeostasis (88). 
Another epi[INVESTIGATOR_018] -specific growth factor secreted by [CONTACT_348064] (HGF). 
Previously, HGF was found to stabilize the integrity of pulmonary endothelial cells by [CONTACT_348065] (89, 90). MSCs have also been reported to 
produce an inflammatory factor called TSG -6, which reduces the size of acute myocardial 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 10  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
infarction in mouse studies and also reduces the severity of acid- induced lung injury in mice 
(91). 
1.4 Nonclinical Safety and Efficacy Studies  
In anticipation of a clinical trial, we established a collaboration with NIH sponsored Production 
Assistance for Cellular T herapy (PACT) Group in the University of Minnesota (Principal 
Investigator: [INVESTIGATOR_347971], MD) for the production of cGMP clinical grade, cryopreserved 
hMSCs. In additional experiments in the ex vivo perfused human lung, these clinical grade 
hMSCs were effective in both endotoxin and live E. coli lung injury models in restoring the rate 
of AFC over [ADDRESS_432322] non -
infectious model of lung injury (hydrochloric acid instillation) and then randomized to placebo 
and three different doses of intravenous hMSCs from the University of Minnesota. The studies 
were carried out over 6 h. There were no respi[INVESTIGATOR_347972] (doses of 1, 5, and 10 x 106 cells/kg).  
 We also have completed a study  with hMSCs in sheep with ALI over 24 hours  (Sheep Study 1) . 
The sheep were injured with inhalation of hot cottonwood smoke and instilla tion of live  
P. aeruginosa bacteria in both lungs . Sheep were treated with intravenous hMSCs (either 5 or 10 
x 10
6 cells/kg) that had been washed to remove all of the DMSO and reconstituted in Plasma-
Lyte A or they were treated with Plasma-Lyte A in the control sheep. The treatment was given 1 
hour after the injury. There was a significant improvement in oxygenation (PaO 2/FiO2 mm Hg) 
at [ADDRESS_432323] -
mortem extravascular lung water was lower in the sheep treated with the higher dose (10 x 106 
cells/kg) compared to controls. The hMSCs were well tolerated with no infusion related changes 
in pulmonary or systemic hemodynamics or oxygenation in Sheep Study 1.   We completed a secon d sheep study (Sheep Study 2  in 2012, n=12) in which ALI was again 
induced with inhaled cottonwood smoke and instillation of live P. aeruginosa bacteria in both 
lungs to test the safety of giving two doses of hMSCs (1 hour and 18 hours after the injury). 
Also, in contrast to Sheep Study 1, in this second sheep study, the hMSCs were administered 
with 2.5% DMSO (i.e., cells not washed to remove the DMSO)  and the sheep were pre- treated 
with diphenhydramine and low dose hydrocortisone.   In these [ADDRESS_432324] six sheep experiments (each one paired with a control) 
indicated that the severity of sepsis was greater in these sheep than in the prior group 1 sheep 
(2011), as reflected by [CONTACT_348066], lower systemic blood pressure,  and lower urine 
output. Five of these 6 sheep died before 24 hours, 2 sheep even before 18 hours . There was a 
protocol of euthanasia guided by a low level of systemic blood pressure and low oxygenation.   In addition to the above observations regarding mortality, there was no evidence of improvement in the oxygenation (P/F ratio) in the first [ADDRESS_432325] six treated sheep. This raised some concern that perhaps administering the MSCs with DMSO decreased the efficacy of  the MSC therapy.  
 
Date:  February 17, [ADDRESS_432326] group 1 (2011) sheep more closely.   Thus, in the next two sheep  (MSC-treated and Plasmalyte control -treated), the dose of bacteria 
was reduced from 2.5 to 1.8 x 10
11 Pseudomonas aeruginosa for instillation into the lungs. The 
result was a pattern of acute lung injury and sepsis that more closely resembled the sheep studies from 2011. These experiments were still carried out with the same protocol of DMSO treatment and two doses of MSCs at one and eighteen hours after onset of acute lung injury. Even with the lower dose of bacteria, the MSC -treated sheep died at ≥  [ADDRESS_432327] four sheep, we continued to use this more moderate dose of bacteria, but returned to the original approach of administration of the MSCs after washing them to remove all the DMSO and without any pre -treatment with Benadryl or hydrocortisone. In the final four 
sheep (MSC -treated and control -treated pairs) , there was evidence of efficacy of improve d 
oxygenation (P/F ratio) as in the prior group 1 experiments from 2011. However, there was still evidence that the second dose of MSCs given at eighteen hours was not tolerated, because one of the MSC-treated sheep died prior to 24 hours.  
 We concluded f rom these studies that (1) DMSO should not be used in our clinical trial and (2) 
that we could not demonstrate preclinical safety for a second dose of hMSCs in this severe model of ALI when the hMSCs were given only [ADDRESS_432328] is Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells ( hMSCs). The investigational product is manufactured at University of Minnesota’s 
Molecular & Cellular Therapeutics (MCT) Facility .  
 The hMSCs are formulated in phosphate buffer saline ( 50%), DMSO (10%), human serum 
albumin (10%) and Plasma-Lyte A (30%), and cryopreserved and stored in bags suspended in 
liquid nitrogen.  Immediately prior to administration, the product is thawed, washed, and re -suspended in Plasma-
Lyte A, a clinical -grade infusible solution for intravenous administration. The product is not 
further cultured or propagated prior to administration.  The placebo group will be treated with an equivalent volume of Plasma -Lyte A. 
 Pre-clinical safety data has been generated  from the ex vivo  perfused human lung as well as small 
animals (mouse and rat)  and large animal (sheep ) safety studies.  In the sheep safety studies, 
Date:  February 17, [ADDRESS_432329] been treated with intravenous hMSCs at doses of either 5 x 106 cells/kg or  
10 x 106 cells/kg. 
 
The initial proposed Phase 1 clinical study will evaluate  single dose treatments of  1 x 106 
cells/kg, 5 x 106 cells/kg and 10 x 106 cells/kg.  The placebo- controlled Phase 2 study will 
evaluate the single -dose treatment of 10 x 106 cells/kg, or the maximum tolerated cell dose from 
the Phase [ADDRESS_432330] 
significant trials to date that are relevant for this application are:  
Studies Focused on Lung Disease  
1) A Phase 2 trial evaluating Prochymal for the treatment of moderate to severe chronic 
obstructive pulmonary disease (COPD, Osiris Therapeutics) involving 62 patients in a randomized, double -blinded, placebo controlled trial ([STUDY_ID_REMOVED]) . The six-month 
interim data analyses demonstra ted that Prochymal significantly decreased the level of C -
reactive protein in patients compared to placebo but did not improve pulmonary function. The primary endpoint was safety, and secondary endpoints include changes in pulmonary function tests, exercis e capability and quality of life . Subjects received 100 x 10
6 
cells/infusion and received 4 weekly infusions (D. Weiss, personal communication) . No 
safety concerns were identified between the placebo and treated groups.  
 
2) Two Phase [ADDRESS_432331] derived mesenchymal stem 
cells for the treatment of severe bronchopulmonary dysplasia in neonates up to 6 months or 14 days respectively, one randomized and the other open- labeled, single -center 
([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]) . Both trials will involve the intra -tracheal 
administration of hMSCs (3 x 10
6/kg for [STUDY_ID_REMOVED] and 10 or 20 x 106/kg for 
[STUDY_ID_REMOVED]). The primary outcomes measured will include the number and severity of 
adverse reactions and/or the relationship between the cytokine concentrations in the BAL 
fluid and pulmonary artery pressure.  
 
3) A Phase 1 trial evaluating the treatment of idiopathic pulmonary fibrosis (IPF) with 
human placental derived mesenchymal stem cells ( [STUDY_ID_REMOVED]). This is an open- label, 
single center, non- randomized dose -escalation evaluation of the safety and feasibility of 
mesenchymal stem cell treatment for subjects diagnosed with IPF . A total of up to eight 
subjects will be enrolled in the study . The first 4 patients will receive a dose of 1 x 106 
placenta-derived mesenchymal stem cells/kg. The Data Safety Management Board 
(DSMB) will carry out an interim safety analysis when these first [ADDRESS_432332] all undergone their 3- month study visit. Should no serious adverse events be documented 
due to the infusion of mesenchymal stem cells, a subsequent 4 patients will receive IV 
infusions of 2 x 10
6 placenta- derived mesenchymal stem cells /kg.  
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 13  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
4) A Phase [ADDRESS_432333] the safety and feasibility of intravenous administration of 
autologous human bone marrow derived mesenchymal stem cells after one- sided lung 
volume reduction surgery (LVRS) and prior to a second LVRS procedure for patients 
with severe pulmonary emphysema ([STUDY_ID_REMOVED]). The study design is an open label, non-randomized, non- blinded, prospective clinical trial. Subjects will undergo two 
operations, initially on one lung without pre -surgical infusion of bone marrow derived 
hMSCs, followed by a second surgical procedure on the contralateral lung, which is preceded by [CONTACT_348067], [ADDRESS_432334] Disease, Crohn’s, Acute 
Myocardial Infarction, Acute Kidney Injury and Diabetes  
5) Two Phase 3 trials using Prochymal (Adult allogeneic mesenchymal stem cells, Osiris 
Therapeutics) in severe refractory graft vs. host disease (GvHD ): one that was not steroid 
responsive and another that received hMSCs as part of first line therapy ([STUDY_ID_REMOVED] 
and [STUDY_ID_REMOVED]). Both trials were placebo controlled and did not meet their endpoints. However, in the steroid refractory trial, there was a statistically significant improvement 
over placebo in patients with gastrointestinal and liver GvHD. The dosing regimen for the hMSCs was 2 x 10
6 cells/kg intravenously twice a week for 4 weeks. These trials were 
inspi[INVESTIGATOR_347973] 2 results (92), which showed an overall response rate of 94% 
and complete remission rate of 77% among 32 patients who received hMSCs for acute 
GvHD. 
 
6) A Phase 3 trial using Prochymal  (Osiris Therapeutics) for the induction of remission in 
subjects experiencing treatment -refractory moderate -to-severe Crohn's disease 
([STUDY_ID_REMOVED]). The primary outcome measured will be disease remission (Crohn’s 
Disease Activity Ind ex at or below 150) within a 28- day timeframe . A low dose (600 x 
106 cells total over four intravenous infusions in two weeks) and a high dose (1200 x 106 
cells delivered intravenously in four infusions over two weeks) will be tested.  
7) A Phase 2 trial using Prochymal (Osiris Therapeutics) in patients following an acute 
myocardial infarction ([STUDY_ID_REMOVED]) . The study is currently enrolling patients (220 
patients, randomized, double -blinded, placebo controlled) . The primary endpoint is left 
ventricular systolic volume; secondary endpoints are measurements of left ventricular ejection fraction, infarct size and major adverse cardiovascular events . Subjects receive a 
single intravenous infusion within 7 days following an acute myocardial infarction. Note that this group completed a double blind, placebo- controlled, dose -ranging (0.5, 1.6, and 
5 million cells/kg) study of 53 patients . Left ventricular ejection fraction improved by 
[CONTACT_51541], as did the forced expi[INVESTIGATOR_12194] (FEV1) in patients treated with hMSCs vs. placebo. There were similar rates of adverse events (5.3/patients post hMSCs 
vs. 7/patient in placebo, n = 53 total) ( 93). 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 14  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
8) A Phase 1/2 trial studying the efficacy of intramyocardial  injections of autologous human 
mesenchymal stem cells in patients undergoing cardiac surgery (Prometheus, NHLBI 
Sponsored, [STUDY_ID_REMOVED]) . This randomized, double -blinded, placebo controlled study 
is currently enrolling patients (planned enrollment 45 patients). Primary outcomes are incidence of serious adverse events at 6 months including the incidence of sustained ventricular arrhythmias, ectopic tissue formation or sudden unexpected death. Dosage used will be 10 to 20 intramyocardial injections of 2 to 20 million hMSCs for a total of  
2 x 10
7 to 2 x 108 cells total.  
 9) A randomized, multi -center, double -blind, placebo- controlled study of AC607 ( hMSCs) 
for the treatment of acute kidney injury in cardiac surgery subjects (AlloCure Inc, [STUDY_ID_REMOVED]). Dosage is a single injection of 2 x 10
6 hMSCs/kg. The primary endpoint 
is time to kidney recovery, defined as a post -operative serum creatinine return to pre -
operative baseline values within 30 days of dosing.   
10) There are >[ADDRESS_432335] for the treatment of Diabetes type 1 and 2 with mesenchymal stem cells . One relevant  trial is a Phase 2, multicenter, randomized, 
double-blind, placebo controlled study to evaluate the safety and efficacy of Prochymal 
(Osiris Therapeutics) for the treatment of  recently diagnosed Type 1 Diabetes Mellitus 
([STUDY_ID_REMOVED]). The dosage is not specified. The primary endpoint will be the 
measurement of C -peptide AUC response (mixed meal tolerance test) . Secondary 
outcomes will be the measurements of peak C -peptide response, basal C -peptide response, 
total daily insulin dose, glycosylated hemoglobin (HbA1c), number of severe and documented hypoglycemic events and changes in levels of GAD or IA -[ADDRESS_432336] studying the safety or efficacy of hMSCs in 
ALI/ARDS . The safety record for hMSCs prepared by [CONTACT_348068], according to published literature and information available on clinical trials.gov. Serious infusion- related or delayed toxicities have not been associated with either 
autologous or allogeneic hMSCs in adult and pediatric recipi[INVESTIGATOR_347974], the patient population most studied to date (94). Osiris Therapeutics has 
sponsored clinical trials of Prochymal (allogeneic unrelated donor hMSCs) that have include d 
over 2000 patients to date . In a randomized, placebo- controlled, dose -escalation safety study of 
Prochymal in patients with acute myocardial infarction, adverse events were comparable for the hMSC- and placebo -treated groups, and no adverse events were a ttributable to hMSCs 
administration (93). Up to 5 x 10
6 cells/kg were administered in this study.  
1.7 Potential Benefits and Risks to Human Participants  
1.7.1 Potential Benefits  
The benefits from hMSCs in the treatment of ARDS remain unknown. The benefit of 
participation in this study is the knowledge gained for the benefit of future patients . The 
mortality rate of moderate- to-severe ARDS (the target population for this trial) is approximately 
30-40%. Administration of hMSCs may have a benefit on mortality in this patient population. 
Study subjects may have a direct benefit from administration  of hMSCs. Furthermore,  if hMSCs 
Date:  February 17, [ADDRESS_432337] a major benefit to society given the high  
mortality rate associated with this condition.  
1.7.2 Potential Risks  
[IP_ADDRESS] Overview  
The main potential risks of participation in this study are those associated with administration of 
the investigational agent. There are additional minor risks associated with study -related 
procedures as detailed below . 
[IP_ADDRESS] Cardiovascular and Respi[INVESTIGATOR_347975] a fall in systemic blood pressure, rising vasopressor dose, a rise in heart rate, an increase in arterial carbon dioxide concentration, or a fall in oxygenation. As detailed below, patients will be monitored continuously during the infusion for these signs/symptoms and the infusion will be terminated if certain clinical criteria or met or there is concern for worsening hemodynamics or oxygenation on the part of the study investigators. 
[IP_ADDRESS] Risks of Transfusion Reaction 
Known potential side effects of blood product transfusion include transient fever or chills. As per 
established regulatory requirements, bone marrow donors are prescreened for infection, reducing 
the risk of infection with HIV or hepatitis B or C from the hMSCs cell product . Patients may 
experience more severe or life- threatening transfusion reactions, but these are exceedingly rare. 
Patients will be monitored during the infusion for signs of a transfusion reaction (urticaria or 
rash, bronchospasm) and medications will be readily available to treat a life -threatening 
transfusion reaction, should such a reaction occur. 
 
[IP_ADDRESS] Risks of blood draws  
All patients will have blood drawn for research purposes. Most blood will be drawn through in-dwelling catheters. Risks of drawing blood percutaneously are minor and include bleeding, 
bruising and infection.
 
[IP_ADDRESS] Reproductive risks  
There may be an unexpected risk to an unborn or nursing child. Pregnant and breastfeeding women will be excluded from participation in the study.  
[IP_ADDRESS] Mini-bronchoalveolar lavage (Mini- BAL) 
In the Phase 2 clinical trial, we will obtain mini- bronchoalveolar lavage (mini -BAL) on day 2 
after the infusion of hMSCs. The known potential risk of  mini-BAL includes transient 
deterioration of oxygenation or respi[INVESTIGATOR_347976], requiring an increase in ventilator 
settings. The exclus ion of study subjects who require high levels of ventilatory support from this 
procedure will minimize the risk of this complication. We will also exclude patients at risk for 
complicatio ns of the mini -BAL procedure including patients with significant bleeding disorders 
or elevated intracranial pressure using clear, predetermined criteria that are used in clinical 
practice. We will not perform a mini- BAL in the Phase 1 dose escalation trial or prior to hMSCs 
Date:  February 17, [ADDRESS_432338] the efficacy of hMSCs within the airspaces, which is a primary 
proposed biological site of action.  
1.8 Study Rationale  
Pre-clinical data from the ex vivo perfused human lung as well as small animal (mouse and rat) 
and large animal (sheep ) studies has been generated demonstrating the potential efficacy and 
safety of h MSCs administration for the treatment of ALI/ARDS . Based on these studies, we 
propose a Phase 1 dose escalation trial followed by a Phase 2 randomized, double blind, placebo 
controlled clinical trial of hMSCs for the treatment of moderate- to-severe ARDS, a condition 
that remains associated with mortality rates in the range of 30 -40%. 
 
2 Study Objectives 
2.1 Primary Objective  
The primary objective of this study is to assess the safety of intravenous infusion of hMSCs in 
patients with ARDS.  
2.2 Secondary Objective  
The secondary objectives of this study are to assess the potential efficacy of intravenous inf usion 
of hMSCs in patients with ARDS and to acquire mechanistic data regarding the activity of 
hMSCs in patients with ARDS.  
 
  
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 17  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
3 Study Design  
This clinical study design starts with an open label dose escalation Phase 1 study that rolls into a 
randomized, double-blinded placebo-controlled Phase 2 study. 
3.1 Phase 1 Study Design  
Phase 1 is an open  label dose escalation pi[INVESTIGATOR_347977] a single infusion of hMSCs. There are 3 cohorts with 3 
subjects/cohort who will receive doses of 1 x 106 cells/kg, 5 x 106 cells/kg, and 10 x 106 cells/kg.  
The first subject in each cohort will receive an infusion and will be observed for 7 days prior to 
enrollment of the remaining subjects in that cohort. The scientific review committee (SRC ) 
made-up of two investigator s and the study medical monitor, will review a [ADDRESS_432339] in the cohort by [CONTACT_577].  
• If there are any concerns on the part of the SRC or if the first subject has met the stoppi[INVESTIGATOR_347978] ( pre-specified infusion associated event or serious adverse event including 
death within 7 days ), enrollment will be suspended pending review by [CONTACT_348069] (DSMB).  
• If stoppi[INVESTIGATOR_347979],  and there are no concerns by [CONTACT_12217], the next two 
subjects in that cohort may be treated.  
The second and third subjects in the cohort may be enrolled concurrently; however if the second 
subject experiences a pre- specified clinically important event or unexpected serious adverse 
event including death prior to enrollment /dosing of the third study subject, enrollment /dosing 
will be suspended pending review by [CONTACT_4318]. 
 After completion of enrollment of each study cohort  and 7 days of follow -up for all 3 individuals 
in the cohort , an aggregate 7 day report of clinical data and all adverse events will be reviewed 
by [CONTACT_348070].   After completion of the Phase 1 study (28 days of follow -up for all nine study subjects ), the SRC 
will review the data and propose a cell product dose for the Phase 2 study. This recommendation 
will be submitted to the DSMB for approval prior to initiating the Phase 2 study. For planning 
purposes, Phase 2 has been designed using the higher dose of  10 x 10
6 cells/kg, assuming it will 
be the maximal tolerated dose . 
 Importantly, there is the possibility that patients may be enrolled in the study but not receive hMSCs due to clinical instability prior to the cell infusion (see Section 7.4); since this is a safety 
study, three subjects must be treated with hMSCs at each  dose prior to any consideration of dose 
escalation by [CONTACT_348071].  Therefore, additional subjects may be enrolled to complete 
the three subjects per dose. 
3.2 Phase 2 Study Design  
Phase 2 is a randomized, double -blinded placebo- controlled study using the  10 x 10
6 cell/kg dose 
of hMSCs or the maximal tolerable dose as determined by [CONTACT_4318]. Subjects will be 
randomized in a 2:1 randomization scheme to receive hMSCs or Plasma-Lyte A placebo; the 
Date:  February 17, [ADDRESS_432340] 
(either hMSCs or the Plasma -Lyte A placebo) as described in Section 7.4.  
 
The DSMB will review [ADDRESS_432341] ; enrollment will continue during DSMB review . During 
Phase 2, all pre-specified clinically important events and unexpected serious adverse events 
including death will be reported to the DSMB on an ongoing basis; the study will be stopped for 
a safety evaluation by [CONTACT_348072]-
specified clinically important events or unexpected serious adverse events EXCEPT death since 
death will be common in this critically ill population due the nature of the underlying illness (e.g., ARDS).  
 
4 Endpoints  
Analysis of the primary  and secondary endpoints will be conducted on an as-treated basis since, 
as described in detail in Section 7.4, there is the potential for subjects to be consented for study 
participation but to not receive treatment because of clinical instability due to the severity of 
their underlying medical conditions. 
4.1 Primary Study Endpoint: Phase [ADDRESS_432342] . This analysis will be largely descriptive in nature  for Phase 1 , but will 
also examine the incidence of pre -specified infusion associated events  and (2) unexpected severe 
adverse events in ARDS patients treated with hMSCs.  
 Because the infusion of hMSCs could theoretically, as described above, cause t ransient occlusion 
of the pulmonary microcirculation which could be associated with a fall in systemic blood 
pressure, rising vasopressor dose, a rise in heart rate, an increase in arterial carbon di oxide 
concentration, or a fall in oxygenation, patients will be monitored closely during the study infusion for changes in these parameters. These events will be considered pre-specified infusion 
associated events if they occur within 6 hours of the hMSCs infusion. 
 Pre-specified infusion associated events will be defined as : 
 
Within 6 hours of the hMSCs infusion:  
1. An increase in vasopressor dose greater than or equal to the following: 
o Norepi[INVESTIGATOR_238]: 10 mcg/min 
o Phenylephine: 100 mcg/min 
o Dopamine: 10 mcg/kg/min  
o Epi[INVESTIGATOR_238]: 0.1 mcg/kg/min 
o Addition of a third vasopressor 
2. New ventricular tachycardia, ventricular fibrillation or asystole  
3. New cardiac arrhythmia requiring cardioversion  
4. Hypoxemia requiring an increase in FiO2 of 0.2 or more and an increase i n PEEP 
of 5 or more to maintain Sp02 in the target range of 88-95%  
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 19  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
5. Clinical scenario consistent with transfusion incompatibility or transfusion -related 
infection (e.g. urticaria, new bronchospasm) 
 
Within 24 hours of the hMSCs infusion: 
1. Any cardiac arrest  or death 
 
We will also systemically collect and review the incidence and nature of serious adverse events that are different from what is expected in the clinical course of a critically ill patient with A RDS 
for the duration of the c linical trial.   
 Expected events for ARDS  are untoward clinical occurrences that are perceived by [CONTACT_348073]. Examples of adv erse events that are 
expected in the course of ARDS include transient hypoxemia, agitation, delirium, nosocomial infections, skin breakdown, and gastrointestinal bleeding.  Such events, which are often the focus of prevention efforts as part of usual ICU care, will not be considered reportable adverse events unless the event is considered by [CONTACT_196753], or unexpectedly severe or frequent for an individual patient with A RDS.  Examples 
of unexpectedly frequent adverse events would be repeated epi[INVESTIGATOR_347980].  This would be in contrast to an isolated epi[INVESTIGATOR_330682] (e.g. Sp0
2 ~85%), related 
to positioning or suctioning.  This latter event would not be considered unexpect ed by [CONTACT_6073], 
severity or frequency.    For the Phase [ADDRESS_432343] or 
death occur ring within 24 hours  of hMSCs administration and unexpected severe adverse events 
in ARDS patients treated with hMSCs compared to patients treated with placebo.  
 
4.2 Secondary Endpoints: Phase [ADDRESS_432344] three categories  of efficacy endpoints  in the Phase 2 trial : respi[INVESTIGATOR_696], systemic and 
biologic.  
 
1. Respi[INVESTIGATOR_696] : Respi[INVESTIGATOR_347981]: 
• The ALI score [Lung Injury Score (LIS)] ( Appendix B) at day 3, since improvement in 
the LIS has been shown to be associated with other clinical outcomes (5, 95, 96), 
including an increased number of ventilator free days and improved survival. The LIS is 
a composite scoring system including the PaO
2/FiO2, the level of positive end- expi[INVESTIGATOR_22325], the extent of infiltrates on the chest radiograph, and static respi [INVESTIGATOR_347982].  
• The other respi[INVESTIGATOR_347983] 2/FiO2 ratio and oxygenation 
index (OI) at day 3, which incorporates mean airway pressure and the PaO2/FiO2. OI is 
independently predictive of mortality in patients with ALI ( 97, 98).  
 
2. Systemic : Efficacy endpoints will include : 
• Mean SOFA score (99) at day 3 as well as  
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 20  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
• Ventilator-free, ICU -free, vasopressor-free, and organ failure free days and  
• 60 day all- cause mortality , although this initial clinical trial of 60 patients will be 
underpowered for these endpoints.  
 
Ventilator Free Days ( VFDs) to day [ADDRESS_432345] the calculation of VFDs. If a 
patient was receiving  assisted breathing at day 27 or dies prior to day 28, VFDs will  be zero. 
Patients transferred to  another hospi[INVESTIGATOR_274337] 28 
to assess this endpoint.  To assess organ failure, we will measure serum creatinine (renal function), bilirubin (hepatic function), and platelet count (hematology) at day 0, 3, [ADDRESS_432346] abnormal vital sign  
or clinically available lab value for each calendar day (with LOCF for missing values) , 
according to the Brussels Organ Fai lure methodology using the clinically significant organ 
failure thresholds for cardiovascular, renal, coagulation and hepatic failure  (100). Patients 
will be followed for development or resolution of organ failures to death, hospi[INVESTIGATOR_274334] 14, whichever comes first. Each day a patient is alive and free of an organ failure will be scored as an organ failure- free day. Any day that a patient is alive and free of 
all 4 organ failures will represent days alive and free of all organ failure.  
 3. Biologic : Biological endpoints will include: 
• A plasma biomarker of lung epi[INVESTIGATOR_196648] (RAGE) , measured at baseline at day 3  
• Plasma pro- and anti -inflammatory markers (interleukin -6, interleukin-8, interleukin-10 
and interleukin- 1Ra), measured at baseline and day 3  
• Plasma biomarkers of endothelial injury ( vWF, Ang- 2), measured at baseline and day 3  
• Plasma markers of change in other organ functi on (creatinine), measured at baseline, day 
3 and day 7 
• Plasma biomarkers that may reflect the paracrine activity of the administered hMSCs 
(Ang-1 and KGF) , measured at baseline and day 3  
• A marker of lung epi[INVESTIGATOR_322483] (total protein concentration  in a mini-BAL 
obtained [ADDRESS_432347] infusion) as well as the total and differential cell count in the mini-BAL specimen in the Phase 2 study. 
5 Study Population and Enrollment  
5.1 Number/Source/Screening 
The Phase 1 trial will enroll 9 patients over 6-9 months and the Phase 2 trial will enroll 60 
patients over a 1 -2 year interval. Patients with ARDS will be recruited from ICUs  at multiple 
study centers.  
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 21  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
 
Study coordinators will screen ICUs daily to identify potential candidates for enrollment. Permission to approach patients and/or their families will be requested from the attending 
physicians. All patients meeting the inclusion criteria will be entered into a screening log. If the patient is not enrolled, the screening log will include information exp laining why enrollment did 
not occur (exclusion criteria, attending physician denial, patient refusal, etc; see Appendix C for 
a listing of the de -identified data to be collected on screened, non -enrolled subjects).  
5.[ADDRESS_432348] all 
be present within a 24-hour time period and at the time of enrollment. 
 Acute onset (defined below) of:  
1. A need for positive pressure ventilation by [CONTACT_348074] a PaO
2/FiO2 
ratio < [ADDRESS_432349] pressure (PEEP ). A patient 
may be included if the PaO 2/FiO2 ratio < 200 with < 8 cm H 2O PEEP if there is a 
contraindication to increased PEEP: evidence of barotrauma ( see Appendix K ). 
2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph, and  
3. No clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial 
Occlusion Pressure (PAOP) less than or equal to 18 mm Hg.  
 
• “Acute onset” is defined as follows: the duration of the hypoxemia criterion (#1) and the 
chest radiograph criterion (#2) must be ≤28 days at the time of randomization.  
• Infiltrates  considered “consistent with pulmonary edema” include any patchy or diffuse  
opacities not fully explained by [CONTACT_27225], atelectasis, or effusion or opacities known to be 
chronic (> 28 days). The findings of vascular redistribution, indistinct vessels, and indistinct cardiac borders are not considered “consistent with pulmonary edema”. 
• If a patient meets the first two inclusion criteria but has a PAOP (Pulmonary Arterial 
Occlusion Pressure, also known as the Pulmonary Arterial Wedge Pressure) that is initially 
greater than [ADDRESS_432350] for more than 12 hours after 
the PAOP has declined to ≤ [ADDRESS_432351] -feeding  
4. Prisoner 
5. Presence of any active malignancy (other than non- melanoma skin cancer) that required 
treatment within the last 2 years  
6. Any other irreversible disease or condition for which 6- month mortality is estimated to be 
greater than 50%  
7. Moderate to severe liver  failure (Childs -Pugh Score > 12)  
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 22  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
 
 
Measure 1 point 2 points 3 points Units 
Bilirubin (total)  <34 
(<2) 34-50 (2-3) >50 (>3) μmol/l 
(mg/dl) 
Serum Albumin  >35 28-35 <28 g/l 
INR  <1.7 1.71-2.20 > 2.20 no unit 
Ascites None Suppressed with 
medication  Refractory  no unit 
Hepatic 
Encephalopathy   None Grade I-II (or 
suppressed with 
medication)  Grade III-
IV (or 
refractory)  no unit 
 
 8. Severe chronic respi[INVESTIGATOR_347945] a PaCO
2 > 50 mm Hg or the use of home oxygen 
9. Patient, surrogate, or physician not committed to full support (Exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from 
cardiac arrest).  
10. Major trauma in the prior 5 days 
11. Lung transplant patient 
12. No consent/inability to obtain consent 
13. Moribund patient not expected to survive [ADDRESS_432352] 3 months 
16. No arterial line/no intent to place an arterial line  
17. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol 
18. Currently receiving extracorporeal life support ( ECLS) or high -frequency oscillatory 
ventilation (HF OV) 
 
Rationale for Exclusions 
Criteria 1: Patients less than 18 years old are excluded because of limited clinical trial data with 
hMSCs in subjects younger than 18 years. Criteria 2: Greater than 96 hours would diminish the likelihood of efficacy Criteria 3  and 4: Standard exclusion of vulnerable patient populations 
Criteria 5  and 6: Those with active malignancies within the past 2 years or  other irreversible 
disease or condition for which 6- month mortality is estimated to be greater than 50% will be 
excluded because these individuals are at an increased risk of death  
Criteria 7, 8 , 9 and 13: Intended to exclude patients unlikely to survive to the  day 28 primary 
study endpoint or whose underlying condition or ventilation management complicates 
assessment of the secondary endpoint of VFDs. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 23  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Criteria 10 and 11: The pathogenesis of trauma -associated ARDS  and ARDS post -lung 
transplant may  be different than that of other forms of ARDS, and the intent is to focus on a 
group of severely ill patients with similar pathogenetic mechanisms to reduce heterogeneity  
Criteria 14 and 15: Intended to exclude patients at increased risk if pulmonary arterial pressures 
increase after administration of MSCs . 
Criteria 16: Given Phase 1/2 nature of study, continuous blood pressure monitoring is a 
mandatory component of the protocol. 
Criteria 17 and 18: Intended to exclude patients in which the ECLS circuit or the use of  
alternative ventilation or fluid management strategies  would complicate  assessment of primary 
and secondary endpoints. Those on ECLS are also excluded because the effect of the ECLS 
circuit on MSC half-life is unknown. 
5.[ADDRESS_432353] onset 
of ARDS, as per the Berlin Definition of ARDS: 
• Bilateral opacities not full explained by [CONTACT_190371], lobar/lung collapse, or nodules; 
PaO2/FIO2 < 300 mm Hg with PEEP or CPAP ≥ 5 cm H2O not fully explained by [CONTACT_21661]; within 1 week of known clinical insult or new/worsening respi[INVESTIGATOR_1856].    
All ARDS criteria must occur within the same [ADDRESS_432354] be initiated within one and four  hours respectively (if not already being utilized). The fluid 
management str ategy will be held for the four  hours prior and the six hours after the MSC 
infusion.  
5.[ADDRESS_432355] Recruitment and Informed Consent  
Study subjects will be recruited in the ICU by a study investigator. Because these study subjects 
may be unable to consent for themselves, written informed consent will be obtained from a 
surrogate where appropriate. Written informed consent will be obtained by [CONTACT_348075]. No study procedures will be conducted before obtaining informed consent. If consent is obtained from a surrogate, the study participant will be asked to re-consent to study participation when they regain the ability to consent for themselves.  
5.6 Randomization 
For the Phase 2 trial, after informed consent is given, an assignment will be made by [CONTACT_22123] -
generated randomization to administer either hMSCs therapy or placebo  with a 2:1 allocation to 
the hMSCs:placebo arms . Randomization will occur at the start of the [ADDRESS_432356] an arterial blood gas with a PaO
2/FiO2 ratio < 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 24  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
200 with PEEP ≥ 8 cm H 20 within 6 hours of randomization. ( The PEEP may be < 8 cm H 2O if 
there is a contraindication to higher PEEP as described in Appendix K.) 
 
5.[ADDRESS_432357] is Allogeneic Bone Marrow -derived Human Mesenchymal 
Stem Cells (hMSCs) . The investigational product is manufactured at University of Minnesota’s 
Molecular & Cellular Therapeutics (MCT) Facility . 
 The hMSCs are formulated in DMSO (10%), human serum albumin (5%) and Plasma -Lyte A 
(30%), and cryopreserved and stored in bags suspended in liquid nitrogen.  Immediately prior to administration, the product is thawed, washed, and re -suspended in Plasma -
Lyte A, a clinical -grade infusible solution for intravenous administration. The product is not 
further cultured or propagated prior to administration.  The placebo group will be treated with an equivalent volume of Plasma -Lyte A. 
6.[ADDRESS_432358] clinical infusion pump using a standardized procedure (s ee Appendix G).  
Date:  February 17, [ADDRESS_432359]  
Allogeneic, unrelated donor hMSCs will be manufactured by : 
[CONTACT_348076] (UMMC)  
Clinical Cell Therapy Laboratory ( AABB-accredited, FACT-accredited, CAP #[ZIP_CODE]-01, 
CLIA #24D0688128)  
Molecular and Cellular Therapeutics (MCT)  
[ADDRESS_432360] will be thawed, washed and prepared for intravenous 
administration in the clinical site’s clinical b one marrow transplant (BMT) facility  
(or equivalent)  by [CONTACT_348077].   See Appendix F for cellular product preparation 
instructions. 
6.3.[ADDRESS_432361]  Preparation  
The placebo for the Phase 2 trial  will be the same volume of Plasma-Lyte A (100 mL) .  See 
Appendix F for cellular product preparation instructions. 
6.[ADDRESS_432362]  
As in prior studies of hMSCs (93), the infusion bag will be covered with aluminum foil a t the 
time of product preparation in the clinical site’s bone marrow transplant laboratory so that the 
product is not visible to the investigators or to the clinicians who are administering the product. Personnel in the bone marrow transplant laboratory who will be preparing the study infusion will not be blinded to treatment allocation. 
Date:  February 17, [ADDRESS_432363]  
The hMSCs will be shipped using temperature monitored shippers to the clinical site’s clinical 
bone marrow transplant labora tory (or equivalent) from UMMC. Upon receipt of the of the study 
cellular product, an inventory must be performed and a receipt log filled out and signed by [CONTACT_348078] . Any damaged or unusable study product in a given shipment  will 
be documented in the study files . The investigator must notify the study sponsor of any damaged 
or unusable study treatments that were supplied to the investigator’s site.   
6.7.[ADDRESS_432364]  
The hMSCs will be administered as a single dose following randomization; the clinical bone 
marrow transplant laboratory  will be responsible  for preparing the cellular product or placebo 
and for dispensing the product to study investigators for administration ( Appendix  F).  
 
The study log for each patient will include treatment assignment, assigned dose of hMSCs, lot 
and bag number for each frozen bag of cellular product used . 
6.7.[ADDRESS_432365] be obtained to confirm a PaO
2/FiO2 < 200 on PEEP ≥ 8 cm H 20 within 6 
hours of randomization. ( The PEEP may be < 8 cm H 2O if there is a contraindication to higher 
PEEP as described in A ppendix K.) 
Date:  February 17, [ADDRESS_432366] a serum creatinine, platelet count, total bilirubin and alanine aminotr ansferase (ALT) measured before the 
infusion of the study product for safety monitoring. Blood and urine samples for biomarker measurements will be obtained before the infusion of study product as well.  
 If the patient does not have an arterial line, an ar terial line will be placed prior to administration 
of the hMSCs.
 
7.4 hMSC Administration  
The hMSCs will be administered intravenously according to the following dose schedule. The 
hMSCs will be administered intravenously over approximately 60-80 minutes . 
In the Phase 1 trial , we will enroll 9 patients in a 3 -dose escalation phase ( 1 x 106 cells/kg, 5 x 
106 cells/kg and 10 x 106 cells/kg).  
 
A. In Phase [ADDRESS_432367] dose escalation model, with a plan for safety 
assessments as detailed in Section 3.1.  
 
B. The initial dose will be 1 x 106 cells/kg given intravenously to 3 patients. After approval 
from the DSMB, we will progress to the next dose. The second dose delivered will be 5.0 
x 106 cells/kg given intravenously to [ADDRESS_432368] dose level will be 10.0 x 106 
cells/kg given intravenously to 3 patients. 
 
In the Phase 2 trial, we will enroll 60 patients in a 2:1 blinded randomized placebo-controlled 
design with the dose of 10 x 106 cells/kg (40 patients treated with hMSCs and 20 controls) . 
Safety analyses will be conducted by [CONTACT_8030], and the sponsor and investigators 
will remain blinded . The safety reviews will be conducted after treatment  of 20 and 40 patients, 
and the trial will continue during these analyses.  
Critically ill patie nts often experience minute- to-minute changes in vital signs . 
Investigators will begin the infusion of hMSCs after a stable baseline for 2 hours has been 
observed .  
 
A. Stable baseline will be defined as:  
 
a. Transcutaneous oxygen saturation in the target range of 88 -95% without any 
increase in ventilator settings AND 
b. Stable vasopressor use if the patient requires vasopressors for blood pressure 
support. The dose of vasopressor may be able to be increased a small amount 
during this 2- hour period, predefined as no more than a 5 mcg/min increase in 
norepi[INVESTIGATOR_347984]; no more than a 50 mcg/min increase in phenylephrine dose; 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 28  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
no more than a 5 mcg/kg/min increase in dopamine dose; and no more than a 0.05 
mcg/kg/min increase in epi[INVESTIGATOR_238] . If the patient is on vasopressin, investigators 
will be instructed not to titrate the vasopressin dose during this 2-hour period.  
 
B. The following patients will be considered clinically unstable and will NOT receive 
hMSCs: 
 
a. Patients requiring  an FiO 2 of > 0.8 or  a PEEP of > 20 cm H 2O, in order to 
maintain transcutaneous oxygen saturation in the target range of 88 -95% 
OR 
b. Patients who require 3 vasopressors for blood pressure support and/or the use of > 
0.1 mcg/kg/min epi[INVESTIGATOR_347985] 
c. Patients who do not meet stability criteria in the supi[INVESTIGATOR_2547], as  baseline 
stability period and  infusion must occur in the supi[INVESTIGATOR_2547] 
 
C. Patients who are clinically unstable will be monitored closely; if they achieve a stable baseline within 120 hours of meeting the entry criteria for the study  and at the time of the 
stable baseline still meet criteria for ARDS (PaO
2/FiO2 ≤ 300 with bilateral infiltrates and 
no evidence of left atrial hypertension) with a PEEP of ≥ 8  (or lower PEEP if there is 
evidence of barotrauma) , they can receive the cell product. Thus, patients may be 
enrolled within [ADDRESS_432369] 30 minutes of the baseline stability period. Patients will not receive the MSC infusion if the 
PaO
2/FiO2 ratio is greater than  300 mmHg on this pre -infusion arterial blood gas.  
Arterial blood gases will also be obtained at the end of MSC infusion (~1 hour) and [ADDRESS_432370] continuous monitoring of arterial blood 
pressure, heart rate, rhythm as well as oxygen saturation. Study personnel will be 
available for the duration of the infusion to monitor the patient. Body temperature will be monitored at a minimum at the start, midw ay through, and at the end of the infusion. 
Patients will be monitored closely for other signs of transfusion reaction, e.g., rash, urticaria or wheezing. If there are any signs of a transfusion reaction, the infusion of hMSCs will be stopped immediately. Similarly, if a patient has a pre -specified infusion 
associated event, the infusion will be stopped. The infusion can also be stopped at the discretion of the study investigator if there is any concern about the patient’s status. 
 
7.5 Ventilator Management  
Ventilator management, including weaning, will follow the modified ARDS Network lower tidal 
volume (6 ml/kg PBW) protocol ( Appendix E). Using this ventilator management protocol will 
Date:  February 17, [ADDRESS_432371] 
practice for weaning, weaning strategy will also be controlled by [CONTACT_274412]- based recommendations. This will assure similar weaning methods and 
provide potential benefit to both study groups. This newer weaning strategy is a simplified version of the weaning strategy protocol used in ARDS Network studies ( see Appendix E). 
7.[ADDRESS_432372], then 6 hours and 1, 2, 3, and 7 days (+/- [ADDRESS_432373] sample only ) after the initiation of the study product 
infusion for biomarker measurements, which include measurements of epi[INVESTIGATOR_196648], inflammation and of hMSC administration. Plasma obtained from two 10 ml EDTA anti -
coagulated blood samples will be divided immediately after centrifugation into 0.5 mL and 1 mL  
aliquots and frozen at –70°C. Urine obtained from the patients will be collected in a  40 ml sterile 
cup; 30 mL will be frozen immediately, and 8 mL  will be centrifuged prior to dividing into 4 
equal aliquots and fr eezing at –70°C.  Finally, the blood cell pellet from the baseline blood 
specimen will be collected for DNA banking.  
 A mini-BAL will be performed 2 days (48 hours) after the initiation of the study product infusion in patients in the Phase 2 clinical trial ( See Appendix A, Time-Events Schedule) for total protein 
measurement, a marker of lung epi[INVESTIGATOR_322483].  
7.[ADDRESS_432374] platelets, serum creatinine, total 
bilirubin, and alanine aminotransferase (ALT) measured on day 3 ( +/- 1 day).  In addition, 
patients will have an arterial blood gas and chest x -ray on day 3 (after administration of the study 
cellular product) since these are secondary en dpoints of the Phase [ADDRESS_432375] an arterial line for ABG monitoring on day 3, the ABG 
will not be obtained for study purposes alone. 
Date:  February 17, [ADDRESS_432376] platelets, serum 
creatinine, total bilirubin and alanine aminotransferase (ALT) measured on day 7 (+/- 1 day) 
after administration of the study product for safety monitoring if they are still hospi[INVESTIGATOR_057] . 
7.[ADDRESS_432377] platelets, serum 
creatinine, total bilirubin and alanine aminotransferase (ALT) measured on day 14 ( +/- 1 day) 
after administration of the study product for safety monitoring if they are still hospi[INVESTIGATOR_057] . 
7.[ADDRESS_432378] occurred. Decisions 
about hospi[INVESTIGATOR_347986]; rather such decisions will be made by [CONTACT_348079][INVESTIGATOR_059].  
7.[ADDRESS_432379]-hospi[INVESTIGATOR_347987]-up  
Vital status as well as the need for dialysis will be collected at 6 and 12 months after study enrollment. This data will be collected at 6 months via a structured telephone interview and at 12 
months via an in -person follow up visit with a limited history and physical examination. 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 31  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
8 Data Collection  
8.1 Medical History  
To be collected from patient charts  and patient/surrogate, where applicable . 
1. Demographic and admission data 
2. Pertinent medical history and physical examination  
3. Height; gender, measured body weight; calculated predicted body weight 
4. Time on ventilator prior to enrollment 
5. Type of Admission 
a. Medical  
b. Surgical scheduled 
c. Surgical unscheduled d. Trauma  
6. Acute or chronic renal failure and use of dialysis 
7. Alcohol Use Disorders Identification Test (AUDIT) tool ( Appendix D, to be 
answered by [CONTACT_4676]/surrogate) 
8. Survey of smoking history including  (if need be, will ask patient/surrogate for 
answers): 
• Ever smoker (> 100 cigarettes in lifetime)?  
• If yes, current smoker? • Estimate of pack years (# packs per day) x (# years smoked) • If former smoker, when did the subject quit smoking? 
8.[ADDRESS_432380] randomization but prior to initiation of study drug. 
8.2.1 To Be Collected From Patient C harts 
1. APACHE III Score  
2. Vital signs: Heart rate, systolic and diastolic blood pressure, body temperature, 
mean arterial pressure, central venous pr essure (if available) . 
3. Ventilator mode (including non- invasive ventilation), tidal volume , FiO2 and 
PEEP, inspi[INVESTIGATOR_347988], and mean airway pressures. If on a pressure -
cycling mode, peak pressure during inspi[INVESTIGATOR_347989]. 
4. Arterial PaO 2, PaCO 2, pH and transcutaneous oxygen saturation 
5. Date and time of all creatinine determinations in the [ADDRESS_432381] radiograph – radiographic lung injury score (# of quadrants) 
7. Vasopressors or inotropes (epi[INVESTIGATOR_238], norepi[INVESTIGATOR_238], phenylephrine, 
vasopressin, dopamine > 5 μg/kg/min, dobutamine, phosphodiesterase inhibitors) 
8. Suspected or known site of infection 
9. Baseline platelet count and kidney / liver function tests: creatinine, total bilirubin, 
alanine aminotransferase . Make laboratory measurement s as specified in Study 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 32  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Procedures Section 7.3 if not available  from testing obtained as part of clinical 
care.   
8.3 Assessment after Enrollment: Determination of Stable Baseline for 
hMSCs Administration , Monitoring During and After Infusion Protocol  
 
The following parameters will be measured and recorded every  15 minutes  for the two hour 
period used to establish the stable baseline prior to the hMSC infusion: 
 
1. Respi[INVESTIGATOR_696]: FiO2, PEEP, transcutaneous oxygen saturation; arterial blood gas pH, PaO 2 
and PaCO 2 and additional ventilator parameters will be recorded if clinically available  
2. Cardiovascular: Heart rate, systolic and diastolic blood pressure, vasopressor doses 
 The same clinical parameters will be recorded every [ADDRESS_432382] 30 minutes of the baseline stability period, at the 
end of the hMSC infusion (~1 hour), and 4 hours after the initiation of MSC infusion; additional 
blood gases will be recorded if obtained as part of clinical care as above.  
8.4 Assessment after Enrollment: Reference Measurements  
 
The following data will provide the basis for assessing protocol compliance and safety as well as between-group differences in several efficacy variables. Data for each of the variables will be 
recorded on the days shown in the Time-Events Schedule (Appendix A ) or until death, discharge 
from the ICU, or unassisted ventilation for 48 hours. 
8.4.1 Reference Measurements (to be collected from patient charts)  
 
The following parameters will be measured and recorded at the time of Randomization as well as 
on subsequent dates using values closest in time to 8:00 A.M. on the days specified in the Time -
Events Schedule (Appendix A). The following conditions will be ensured prior to measurements: 
no endobronchial suctioning for 10 minutes; no invasive procedures or ventilator changes for [ADDRESS_432383] daily up to day 7: 
a. Tidal volume, FiO
2, PEEP, inspi[INVESTIGATOR_347988], and mean airway 
pressures 
b. Pressure during inspi[INVESTIGATOR_299355] a pressure targeted mode (PSV, PCV, etc). 
c. Arterial PaO 2, PaCO 2, pH and transcutaneous oxygen saturation 
2. Fluid intake and output 
3. Vital signs: Heart rate, systolic and diastolic blood pressure, body temperature, CVP 
4. Modified Brussels Score data days 0-14 
5. Vasopressor use (Y/N), worst systolic BP, creatinine, bilirubin, and platelet count  for the 
day. The date and value of the highest creatinine between days 15-28 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 33  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
6. Safety laboratory studies; all creatinine and bilirubin measurements will be recorded as 
above. Creatinine, bilirubin and ALT will be measured and recorded as a safety lab s on 
day [ADDRESS_432384] radiograph – Lung Injury Score 
8. Suspected or known infection 
8.4.2 Specimen Collection  
1. Date and time of specimen collection  
2. Time of specimen processing and storage 
8.5 Endpoint Determinations  
3. Vital status at 28 days or until discharged home on unassisted breathing. 
4. Brussels Organ dysfunction failures at days 0-14 
5. SOFA scores at 3, 7 and 14 days 
6. Time of initiation of unassisted breathing (assuming a patient achieves 48 consecutive hours of unassisted breathing) 
7. Need for re -instituting assisted or mechanical ventilation after achieving 48 consecutive 
hours of unassisted breathing 
8. Need for, timing, and duration of dialysis ; change in renal function as measured by 
[INVESTIGATOR_10426]  
9. Status 48 hours after initiation of unassisted breathing  
10. ICU length of stay in calendar days including ICU days after readmission to ICU. 
11. Hospi[INVESTIGATOR_347990] (home, other facility, with or without assisted ventilation)  
8.[ADDRESS_432385] this data through telephone interviews with patients at 6 months and 
an in-person follow up visit with a limited history and physical examination at 12 months. 
 
Date:  February 17, [ADDRESS_432386] a safety signal. The sample size for the Phase 2 portion of the 
trial will be 40 patients in the hMSCs arm and 20 patients in the placebo arm, for a total of 60 
patients. This sample size was determined on the basis of feasibility and in order to generate 
enough clinical and biological data to aid in sample size projections for subsequent Phase 2b/[ADDRESS_432387] statistical tests, inc luding the Pearson’s chi-
square test for categorical variables, analysis of variance and Student’s t -test for continuous 
variables, and Kruskal -Wallis or other non- parametric tests for non -normally distributed 
variables. We will describe the incidence of serious adverse events, including death, as well as the incidence of pre -specified infusion associated events and non- serious adverse events felt to 
be related to the study infusion. Since up to 3 cohorts of subjects will receive escalating doses of hMSCs, as detailed in the full Statistical Analysis Plan, we will compare the incidence of adverse 
events by [CONTACT_348080]’s chi -square test  or the Student’s t -test to compare 
the mean number of adverse events by [CONTACT_14338], depending on the number of AEs observed.   For the Phase 2 study, the group treated with hMSCs will be compared to the placebo control 
group using a variety of baseline patient characteristics, including socio- demographic 
characteristics (age, gender, race), smoking history, acute illness severity (APACHE II I scores, 
non-pulmonary organ failures), and severity of ALI (oxygenation, respi[INVESTIGATOR_347991], 
airway pressures, the 4 -point lung injury score). Here, we will describe the incidence of serious 
adverse events, i ncluding death, as well as the incidence of pre-specified infusion associated  
events and non- serious adverse events felt to be related to the study infusion in the hMSC-treated 
versus placebo arms. Analysis of the primary safety endpoint will be focused on characterizing 
the AE proportion in each treatment arm, whereas the secondary efficacy endpoints will be used for the design of larger efficacy studies. We will again compare the incidence of adverse events 
by [CONTACT_348080]’s c hi-square test or the Student’s t -test. The per-treatment 
arm sample sizes were generated based on an assumption of a 28 -day AE proportion of 30%. In 
this setting, the 95% confidence interval (CI) length for a binomial proportion is 24% ranging 
from 19% to 43%.  
 The Phase 2 part of this trial is not adequately powered for clinical efficacy endpoints such as 
mortality and ventilator free days and has limited power for physiological endpoints  since the 
primary focus of the Phase 2 study is safety. If hMSCs are safe , a larger Phase 2b study will be 
Date:  February 17, [ADDRESS_432388] sizes (the difference in mean values between treatment and control divided by [CONTACT_156970]) . This approach allows us to evaluate the efficacy of hMSCs in a small 
sample size by [CONTACT_348081] 2 trial to effects  observed 
in larger trials of therapi[INVESTIGATOR_347992] . In the case of ARDS, the comparison trials 
would be those of lower tidal volume ventilation ( 4) and fluid conservative therapy (5). We will 
use the incidence of adverse events along with an overall assessment of the potential efficacy of hMSCs using the pre -specified respi[INVESTIGATOR_696], clinical and biological endpoints to make a 
determination as to whether or not a larger Phase 2b study is safe and warranted.  
9.[ADDRESS_432389] Population(s) for Analysis  
The subject population for all study analyses will be the all-treated population, that is, any 
subject randomized into the study who at least starts to receive hMSCs or placebo, regardless of 
whether or not the infusion is completed. This population has been selected instead of an all -
randomized population because study subjects must achieve a clinically stable baseline prior to 
study drug infusion. It is possible that some enrolled subjects may never meet these criteria for 
clinical stability and thus would never be treated . Therefore, the all-treated population an alysis 
will most accurately reflect the effects of the study infusion  and allow us to analyze sufficient 
subjects who receive the study drug to detect a safety concern, if one exists. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 36  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
10 Safety and Adverse Events  
10.1 Definitions  
Investigators will determine daily if any clinical adverse experiences occur during the period 
from enrollment through study day 28. The investigator will evaluate any changes in laboratory 
values and physical signs and will determine if the change is clinically important and different from what is expected in the course of treatment of patients with ARDS.  
 
For this trial, a reportable adverse event is defined as:  
 Any clinically important untoward medical occurrence in a patient receiving study product 
which is different from what is expected in the clinical course of a patient with ARDS, or:  
1. Any clinically important, untoward medical occurrence that is thought to be associated the study product, regardless of the “expectedness” of the event for a patient with ALI.  or: 
2. The following pre-specified infusion associated events  that occur within [ADDRESS_432390] will always be reported as adverse events:  
• If on a vasopressor, an increase in vasopressor dose greater than or equal to the 
following: 
o Norepi[INVESTIGATOR_238]: 10 mc g/min 
o Phenylephine: 100 mcg/min 
o Dopamine: 10 mcg/kg/min  
o Epi[INVESTIGATOR_238]: 0.1 mcg/kg/min 
o Addition of a third vasopressor 
• New cardiac arrhythmia requiring cardioversion or ventricular tachycardia, ventricular fibrillation or asystole  
• Hypoxemia requiring an incre ase in FiO
2 of 0.2 or more and an increase in PEEP 
of 5 or more to maintain Sp02 in the target range of 88-95%  
• Clinical scenario consistent with transfusion incompatibility or transfusion -related 
infection (e.g., urticaria, new bronchospasm) 
3. Any cardiac a rrest or death occurs within [ADDRESS_432391] and may require medical or surgical intervention to prevent one of the outcomes listed above. 
1. ‘Life-threatening ’ means that the patient was, in the view of the investigator, at 
immediate risk of death from the reaction as it occurred . This definition does not include 
a reaction that, had it occurred in a more serious form, might have caused death. Assessment of the cause of the event has no bearing on the assessment of the event’s 
severity. 
Date:  February 17, [ADDRESS_432392] been produced by [CONTACT_196762]. 
All adverse events that do not meet any of the criteria for serious should be regarded as non-
serious adverse events .  
 An unanticipated problem (UP)  is any incident, experience, or outcome that meets all of the 
following criteria  (101): 
• Unexpected, in terms of nature, severity, or frequency, given the research procedures that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and the characteristics of the subject population being studied;  
• Related or possibly related to participation in the research, in this guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459];  
• Suggests that the research places subjects or others at a greater risk  of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
Adverse Event Reporting Period  
Reportable adverse events that occur during the [ADDRESS_432393] or procedures, or unexpectedly severe or frequent for an individual patient with ARDS. Examples of unexpectedly frequent adverse events would be repeated epi[INVESTIGATOR_347980]. 
Date:  February 17, [ADDRESS_432394] to an isolated epi[INVESTIGATOR_330682] (e.g., Sp0 2 ~85%), 
related to positioning or suctioning. This latter event would not be considered unexpected by 
[CONTACT_6073], severity or frequency.   Organ failures related to ARDS or the patient’s underlying condition that are systematically captured by [CONTACT_348082] .  
 All adverse events occurring during the study period must be reported in the patient’s case report 
forms. The clinical course of each event should be followed until resolution, stabilization, or 
until it has been determined that the study treatment or participation is not the cause . Serious 
adverse events that are still ongoing at the end of the study period must be followed up to determine the final outcome . Any serious  adverse event that occurs after the study period and is 
considered to be possibly related to the study treatment or study participation should be recorded and reported immediately  to the study sponsor ( see Section 10.3). 
10.3 Reporting of Serious Adverse Events and Unanticipated Problems  
10.3.1 Investigators’ Reporting Requirements to the Sponsor  
Investigators will report all serious AND unexpected, AND study -related adverse events to the 
study sponsor (who will run the Clinical Coordinating Center for this study) within [ADDRESS_432395] also be notified in a timely manner , as per the IRB’s requirement . The 
investigator will then submit a detailed written report to the study sponsor  and the local IRB (as 
required) no later than 5 calendar days after the investigator discovers the event.   The minimum necessary information to be provided at the time of the initial written report 
includes: 
• Study identifier  
• Study Center  
• Subject number 
• A description of the event 
• Date of onset  • Current status 
• Whether study treatment was discontinued 
• The reason why the event is classified as 
serious 
• Investigator assessment of the association 
between the event and study treatment  
 
10.3.2 Sponsor Reporting: Notifying the FDA  
The study sponsor  is required to report certain study events in an expedited fashion to the FDA . 
These written notifications of adverse events are referred to as IND safety reports. The following describes the safety reporting requirements by [CONTACT_28822]: 
• Within 7 calendar days 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 39  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
Any study event that is : 
– associated with the use of the study drug  and 
– unexpected, and  
– fatal or life -threatening  
 
• Within 15 calendar days 
Any study event that is : 
– associated with the use of the study drug,  and 
– unexpected, and 
– serious, but not fatal or life- threatening  
-or- 
– a previous adverse event that was not initially deemed reportable but is later found to 
fit the criteria for reporting (reporting within 15 calendar days from when event was 
deemed reportable).  
Any finding from tests in laboratory animals that:  
– suggest a significant risk for human subjects including reports of mutagenicity, 
teratogenicity, or carcinogenicity.  
 
Additional IND Reporting Requirements: 
Sponsors are also required to identify in IND safety reports all previous reports concerning similar adver se events and to analyze the significance of the current event in light of the previous 
reports. 
10.3.3 Sponsor Reporting:  Notifying the DSMB  
The study sponsor will report all serious, unexpected, and study -related adverse events to the 
DSMB, by [CONTACT_6968], or teleph one, within 7 calendar days of the study sponsor being notified of the 
event. A written report will be sent to the DSMB within 15 calendar days, and these reports will be sent to investigators for submission to their respective IRBs, as required. The DSMB will also 
review all adverse events during scheduled interim analyses. Sponsor R eporting: Notifying All 
Participating Investigators. 
 
It is the responsibility of the study sponsor to notify all participating investigators, in a written IND safety report, of any adverse event associated with the use of the drug that is both serious 
and unexpected . Additionally, sponsors are also required to identify in IND safety reports all 
previous reports concerning similar adverse events and to analyze the significance of the current 
event in light of the previous reports. IND safety reports will be sent to the participating 
investigators immediately after submission to the IND.  
 The study sponsor will distribute the written summary of the DSMB’s periodic review of adver se 
events to investigators for submission to their respective IRBs in accordance with NIH guidelines.  
10.[ADDRESS_432396] an external Medical Monitor separate from the Investigator/Sponsor and 
who will not be affiliated w ith any of the study sites or participate in any study procedures (e.g., 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 40  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
screening of subjects, consenting of subjects or  surrogates, administration of hMSCs or study 
follow-up). If unblinding the study therapy is necessary to ensure a subject’s safety, this will be 
done by [CONTACT_348083]. If this is done in 
conjunction with the site Principal Investigator, the study sponsor  must be informed within 24 
hours by [CONTACT_648], fax or email of the unblinding event, followed by a detailed written narrative within 48 hours of the event by [CONTACT_079] [INVESTIGATOR_80407].  
 In other circumstances, the medical monitor may choose to unblind him/hers elf if there is 
concern based on the safety data that a type of adverse event may be associated with hMSCs 
treatment; in this case, the medical monitor will inform the study sponsor  that he/she has 
unblended him/herself, but not of the treatment assignment s. 
10.5 Stoppi[INVESTIGATOR_347993] 1 is an open label dose escalation pi[INVESTIGATOR_347977] a single infusion of hMSCs. We plan 3 cohorts with 3 subjects/cohort 
who will receive doses of 1 x 10
6 cells/kg, 5 x 106 cells/kg, and 10 x 106 cells/kg. The first 
subject in each cohort will receive an infusion and will be observed for 7 days prior to enrollment of the remaining subjects in that cohort. A Scientific Review Committee (SRC ) made 
up of two investigators and the study medical monitor , will review a report of clinical data and 
adverse events from the first subject in the cohort by [CONTACT_577].  
• If no pre -specified infusion associated event or unexpected  serious adverse event 
including death is observed and if review of the case report forms does not show any 
concerning events or trends, the SRC may recommend that the next two subjects in that 
cohort may be treated.  
• The SRC will document in writing the rationale for continuing the dosing within that 
cohort. The second and third subjects in the cohort may be enrolled concurrently.  
• If there are any concerns on the part of the SRC or if the first subject has a protocol -
specified infusion- related adverse event or any serious adverse event including death, 
enrollment will be suspended pending review by [CONTACT_4318] .  
• If the second subject experiences a pre- specified infusion associated event or unexpected 
serious adverse event  including death prior to enrollment of the third study subject, 
enrollment will be suspended pending review by [CONTACT_4318].  
• If a subject experiences a pre- specified infusion associated event or unexpected serious 
adverse event including death at a given dos e of hMSC, the DSMB will have the 
discretion to add another subject to the cohort at the same dose or to determine that the 
maximum tolerable dose has been achieved.  
• If another subject is added to the cohort, that subject must have [ADDRESS_432397] in the cohort.  
• Finally, dose escalation cannot proceed unless 3 subjects are successfully enrolled at a 
given dose without a pre -specified infusion associated event or unexpected serious 
adverse event including death prior to day 7. 
 
After completion of enrollment of each study cohort, an aggregate report of clinical data and all 
adverse events will be reviewed by [CONTACT_348084]:  February 17, [ADDRESS_432398]; however, enrollment will not be suspended pending DSMB review. During Phase 2, all pre-specified clinically important events 
and unexpected serious adverse events , including death, will be reported to the DSMB on an 
ongoing basis; the study will be stopped for a safety evaluation by [CONTACT_348085]-specified clinically important event s or unexpected serious 
adverse events EXCEPT death since death will be common in this critically ill population due the nature of the underlying illness (e.g., ARDS).   The Phase [ADDRESS_432399] completed 28 -day follow -up, after which data analysis will 
commence. The Phase 2 study will stop prior to completion  if mandated by [CONTACT_348086] -
appointed DSMB or the FDA due to safety concerns.  
10.6 Medical Monitoring  
It is the r esponsibility of the Principal Investigator [INVESTIGATOR_16462]/her 
site. This safety monitoring will include careful assessment and appropriate reporting of adverse 
events as noted above, as well as the construction and implementation of a site data and safety -
monitoring plan. Medical monitoring will include a regular assessment of the number and type of serious adverse events.  The study will have an external medical monitor who will be available to 
investigators to independently evaluate adverse events and to assist with unblinding, if this becomes necessary.  
10.6.[ADDRESS_432400] 3 members, 2 intensivis ts familiar with the care of patients with ARDS  and a 
biostatistician.  A DSMB Charter will define the DSMB’s responsibilities  as described  below. 
 The DSMB will meet by [CONTACT_348087] 1 trial, after each cohort of 
3 patients  is completed (and earlier if needed)  during Phase 1,  and at the planned interim safety 
analyses (20 and 40 patients) for the Phase 2 trial. At these meetings, the DSMB will review all safety data in aggregate; individual adverse event narratives will also be available to the DSMB for review. At the end of the Phase [ADDRESS_432401] has a pre-specified infusion associated event or unexpected  serious adverse 
event (including death) during the Phase 1 component of the study; the DSMB will also receive 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 42  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
reports of serious, unexpected, and study -related adverse events and unanticipated problems on 
an ongoing basis. 
 The external medical monitor will serve as the lia ison between the DSMB and the study sponsor  
and Principal Investigator. The actual analyses will be conducted by [CONTACT_348088]; who will ensure that the unblinded analyses are not available to study 
investigators.   
• The DSMB chair will be responsible for recording the summary of its various meetings 
and for reporting findings and/or recommendations to the study sponsor and to the funding agency, the NHLBI.  
 
[ADDRESS_432402] of 1996 (HIPAA) . 
Those regulations require a signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of thei r PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authori zation to collect or use PHI, attempts should 
be made to obtain permission to collect at least vital status (i.e. , that the subject is alive) at the 
end of their scheduled study period. 
11.2 Source Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents . Examples of these original documents, and data records 
include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved 
in the clinical trial.  
11.3 Case Report Forms  
The study case report form s (CRFs) are the primary data collection instruments for the study . All 
data requested on the CRF s must be recorded . All missing data must be explained . If a space on 
the CRF is left blank because the procedure was not done or the question was not  asked, write 
“N/D”. If the item is not applicable to the individual case, write “N/A” . All entries should be 
Date:  February 17, [ADDRESS_432403] be initialed and dated . DO NOT ERASE OR WHITE OUT ERRORS . For 
clarification of illegible or uncertain entries, print the clarification above the item, then initial and 
date it. 
11.4 Records Retention  
It is the investigator’s responsibility to retain study essential documents for at least 2 years after 
the completion and publication of the clinical trial. These documents should be retained for a longer period if required by [CONTACT_16477]. In such an instance, it is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to be retained.   
 
12 Study Monitoring, Auditing, and Inspecting 
12.1 Study Monitoring Plan 
The data safet y and monitoring plan for this Phase 1/[ADDRESS_432404] with expertise in Phase 1/[ADDRESS_432405]
.  
 
A separate monitoring plan will be written to specify how the participating clinical sites will be monitored by [CONTACT_456]. 
12.2 Auditing and Inspecting 
The investigator will permit study -related monitoring, audits, and inspections by [CONTACT_1201], the 
sponsor, government regulatory bodies, and University compliance and quality assurance groups of all study related documents (e.g., source documents, regulatory documents, data collection 
instruments, study data etc.) . The investigator will ensure the capability for inspections of 
applicable study -related facilities (e.g. , pharmacy, diagnostic laboratory, etc.). 
 Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_348089]. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 44  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
13 Ethical Considerations  
This study is to be conducted according to US and international standards of Good Clinical 
Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable gov ernment regulations and Institutional research policies and procedures. 
 This protocol and any amendments will be submitted to a properly constituted independent IRB, in agreement with local legal prescriptions, for formal approval of the study conduct . The 
decision of the IRB concerning the conduct of the study will be made in writing to the investigator and a copy of this decision will be provided to the sponsor before commencement of this study . The investigator should provide a list of IRB members and t heir affiliate to the 
sponsor.  All subjects for this study will be provided a consent form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study. The consent form will be submitted with the protocol for review and approval by [CONTACT_271490] . The formal consent of a subject, using the IRB -approved consent form, must be 
obtained before that subject undergoes any study procedure . The consent form must be signed by 
[CONTACT_17257], and the investigator -designated research professional 
obtaining the consent.   
[ADDRESS_432406] with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must ha ve the 
conflict reviewed by a properly constituted Conflict of Interest Committee with a Committee -
sanctioned conflict management plan that has been reviewed and approved by [CONTACT_28833] . All University of [LOCATION_004] investigators will follow the 
University conflict of interest policy.  
[ADDRESS_432407] of References  
1. Ware LB, Matthay MA. The acute respi[INVESTIGATOR_1505]. N Engl J Med. 
2000;34(18):1334- 49. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 45  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and 
outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685- 93. 
3. Matthay MA, Zimmerman GA. Acute lung injury and the acute respi[INVESTIGATOR_1505]: four 
decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol. 
2005;33(4):319- 27. 
4. Ventilation with lower tidal volumes as  compared with traditional tidal volumes for acute lung 
injury and the acute respi[INVESTIGATOR_1505]. The Acute Respi[INVESTIGATOR_196700]. N Engl J Med. 2000;342(18):1301- 8. 
5. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al. 
Comparison of two fluid -management strategies in acute lung injury. N Engl J Med. 
2006;354(24):2564- 75. 
6. Papazian L, Forel JM, Gacouin A, Penot -Ragon C, Perrin G, Loundou A, et al. Neuromuscular 
blockers in early acute respi[INVESTIGATOR_1505]. N Engl J Med. 2010;363(12):1107- 16. 
7. Matthay MA, Ware LB, Zimmerman GA. The acute respi[INVESTIGATOR_1505]. J Clin Invest. 
2012;122(8):2731- 40. 
8. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow.Anal ysis 
of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230- 47. 
9. Dominici M, Le Blanc K, Mueller I, Slaper -Cortenbach I, Marini F, Krause D, et al. Minimal criteria 
for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy 
position statement. Cytotherapy. 2006;8(4):315- 7. 
10. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, et al. Multi -organ, multi -
lineage engraftment by a single bone marrow -derived stem cell. Cell . 2001;105(3):369- 77. 
11. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, et al. Bone marrow -
derived cells as progenitors of lung alveolar epi[INVESTIGATOR_2130]. Development. 2001;128(24):5181- 8. 
12. Wang G, Bunnell BA, Painter RG, Quiniones BC, Tom S, Lanson NA, Jr., et al. Adult stem cells from bone marrow stroma differentiate into airway epi[INVESTIGATOR_1663]: potential therapy for cystic 
fibrosis. Proc Natl Acad Sci U S A. 2005;102(1):186- 91. 
13. Spees JL, Pociask DA, Sullivan DE, Whitney MJ, Lasky JA, Prockop DJ, et al. Engraftment of 
bone marrow progenitor cells in a rat model of asbestos -induced pulmonary fibrosis. Am J Respir 
Crit Care Med. 2007;176(4):385- 94. 
14. Hung SC, Pochampally RR, Hsu SC, Sanchez C, Chen SC, Spees J, et al. Short -term exposure 
of multipo tent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and 
their engraftment in vivo. PLoS ONE. 2007;2(5):e416.  
15. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science. 2002;297(5590):2256- 9. 
16. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003;100(14):8407- 11. 
17. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, et al. Bone marrow -derived 
mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005;33(2):145-52. 
18. Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epi[INVESTIGATOR_2130]. Am J Respir Cell Mol Biol. 2005;33(4):328- 34. 
19. Loi R, Beckett T, Goncz KK, Suratt BT, Weiss DJ. Limited restoration of cystic fibrosis lung epi[INVESTIGATOR_347994] -derived cells. Am J Respir Crit Care Med. 
2006;173(2):171- 9. 
20. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2) -dependent reprogramming of host 
macrophages to increase their interleukin- 10 production. Nat Med. 2009;15(1):42 -9. 
21. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31(10):890- 6. 
22. Aggarwal S, Pi[INVESTIGATOR_347995]. Human mesenchymal stem cells modulate allogeneic immune cell 
responses. Blood. 2005;105(4):1815- 22. 
23. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce 
division arrest anergy of activated T cells. Blood. 2005;105( 7):2821- 7. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 46  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
24. Di Nicola M, Carlo -Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone 
marrow stromal cells suppress T -lymphocyte proliferation induced by [CONTACT_348090]. Blood. 2002;99(10):3838- 43. 
25. Klyushnenkova  E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, et al. T cell 
responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and 
suppression. J Biomed Sci. 2005;12(1):47- 57. 
26. Rasmusson I, Ringden O, Sundberg B, Le Blanc K.  Mesenchymal stem cells inhibit the formation 
of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 2003;76(8):1208- 13. 
27. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells r ecruit 
macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE. 2008;3(4):e1886.  
28. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer from bone- marrow -derived stromal cells to pulmonary alveoli protects  against acute lung injury. Nat 
Med. 2012;18(5):759- 65. 
29. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen- presenting cell maturation and induce T -cell unresponsiveness. Blood. 
2005;105(5):2214- 9. 
30. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappi[INVESTIGATOR_61625] V, Cazzanti F, et al. Human mesenchymal stem cells modulate B- cell functions. Blood. 2006;107(1):367- 72. 
31. Ajuebor MN, Das AM, Virag L, Flower RJ, Szabo C, Perretti M. Role of resident peritoneal 
macrophages and mast cells in chemokine production and neutrophil migration in acute 
inflammation: evidence for an inhibitory loop involving endogenous IL- 10. J Immunol. 
1999;162(3):1685- 91. 
32. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow -derived mesenchymal stem cells improves survival and attenuates endotoxin- induced 
acute lung injury in mice. J Immunol. 2007;179(3):1855- 63. 
33. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al. Interleukin [ADDRESS_432408] of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007;104(26):[ZIP_CODE]- 7. 
34. Geiser T, Atabai K, Jarreau PH, Ware LB, Pugin J, Matthay MA. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epi[INVESTIGATOR_347996]- 1beta-
dependent mechanism. Am J Respir Crit Care Med. 2001;163(6):1384- 8. 
35. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS -induced 
acute lung injury in mice by [CONTACT_348091] 1. PLoS Med. 2007;4(9):e269.  
36. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, et al. Prevention of endotoxin- induced 
systemic response by [CONTACT_167666] -derived mesenchymal stem cell s in mice. Am J Physiol Lung 
Cell Mol Physiol. 2007;293(1):L131- 41. 
37. Xu J, Qu J, Cao L, Sai Y, Chen C, He L, et al. Mesenchymal stem cell -based angiopoietin- 1 gene 
therapy for acute lung injury induced by [CONTACT_348092]. J Pathol. 2008;214(4):47 2-81. 
38. Stagg J. Immune regulation by [CONTACT_145342]: two sides to the coin. Tissue Antigens. 2007;69(1):1- 9. 
39. Chan JL, Tang KC, Patel AP, Bonilla LM, Pi[INVESTIGATOR_127389] N, Ponzio NM, et al. Antigen- presenting 
property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood. 2006;107(12):4817- 24. 
40. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon- gamma -stimulated marrow stromal 
cells: a new type of nonhematopoietic antigen- presenting cell. Blood. 2006;107(6):2570- 7. 
41. Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody 
secretion in human B cells. Scand J Immunol. 2007;65(4):336- 43. 
42. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al. Human 
mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26(1):151- 62. 
43. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. 
Thorax. 2012;67(6):533- 9. 
Date:  February 17, [ADDRESS_432409] of 
human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229- 38. 
45. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram -negative sepsis in mice in part by [CONTACT_348093] y of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 
2012;302(10):L1003- 13. 
46. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J 
Respir Crit Care Med. 2010;182(8):1047- 57. 
47. Matthay MA, Wiener -Kronish JP. Intact epi[INVESTIGATOR_347997]. Am Rev Respir Dis. 1990;142(6 Pt 1):1250- 7. 
48. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respi[INVESTIGATOR_1505]. Am J Respir Crit Care Med. 2001;163(6):1376- 83. 
49. Matthay MA, Folkesson HG, Clerici C. Lung epi[INVESTIGATOR_347998]. Physiol Rev. 2002;82(3):569- 600. 
50. Folkesson HG, Matthay MA. Alveolar epi[INVESTIGATOR_347999]: recent progress. Am J Respir Cell Mol Biol. 2006;35(1):10- 9. 
51. Matalon S, O'Brodovich H. Sodium channels in alveolar epi[INVESTIGATOR_1663]: molecular characterization, biophysical properties, and physiological significance. Annu Rev Physiol. 
1999;61:627- 61. 
52. Eaton DC, Chen J, Ramosevac S, Matalon S, Jain L. Regulation of Na+ channels in lung alveolar 
type II epi[INVESTIGATOR_1663]. Proc Am Thorac Soc. 2004;1(1):10- 6. 
53. Mutlu GM, Sznajder JI. Mechanisms of pulmonary edema clearance. Am J Physiol Lung Cell Mol Physiol. 2005;289(5):L685- 95. 
54. Matalon S, Lazrak A, Jain L, Eaton DC. Invited review: biophysical properties of sodium channels in lung alveolar epi[INVESTIGATOR_1663]. J Appl Physiol. 2002;93(5):1852- 9. 
55. Fang X, Song Y, Hirsch J, Galietta LJ, Pedemonte N, Zemans RL, et al. Contribution of CFTR to api[INVESTIGATOR_2855] -basolateral fluid transport in cultured human alveolar epi[INVESTIGATOR_348000]. Am J Physiol 
Lung Cell Mol Physiol. 2006;290(2):L242- 9. 
56. Brochiero E, Dagenais A, Prive A, Berthiaume Y, Grygorczyk R. Evidence of a functional CFTR 
Cl(-) channel in adult alveolar epi[INVESTIGATOR_1663]. Am J Physiol Lung Cell Mol Physiol. 
2004;287(2):L382- 92. 
57. Mutlu GM, Adir Y, Jameel M, Akhmedov AT, Welch L, Dumasius V, et al. Interdependency of 
beta- adrenergic receptors and CFTR in regulation of alveolar active Na+ transport. Circ Res. 
2005;96(9):999- 1005.  
58. Pugin J, Verghese G, Widmer MC, Matthay MA. The alveolar space is the site of intense 
inflammatory and profibrotic reactions in the early phase of acute respi[INVESTIGATOR_1505]. Crit Care Med. 1999;27(2):304- 12. 
59. Olman MA, White KE, Ware LB, Simmons WL, Benveniste EN, Zhu S, et al. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL- 1 beta-
induced IL- 6 expression. J Immunol. 2004;172(4):[ADDRESS_432410], Bastarache JA, Ware LB, et al. Acute lung injury edema fluid decreases net fluid transport across human alveolar epi[INVESTIGATOR_348000]. J Biol Chem. 2007;282(33):[ZIP_CODE] -19. 
61. Dagenais A, Frechette R, Yamagata Y, Yamagata T, Carmel JF, Clermont ME, et al. Downregulation of ENaC activity and expression by [CONTACT_51004] -alpha in alveolar epi[INVESTIGATOR_1663].  Am J 
Physiol Lung Cell Mol Physiol. 2004;286(2):L301- 11. 
62. Roux J, Kawakatsu H, Gartland B, Pespeni M, Sheppard D, Matthay MA, et al. Interleukin- 1beta 
decreases expression of the epi[INVESTIGATOR_348001]- subunit in alveolar epi[INVESTIGATOR_348002] 
a p38 MAPK -dependent signaling pathway. J Biol Chem. 2005;280(19):[ZIP_CODE]- 89. 
63. Frank J, Roux J, Kawakatsu H, Su G, Dagenais A, Berthiaume Y, et al. Transforming growth factor -beta1 decreases expression of the epi[INVESTIGATOR_348003]1/2- dependent mechanism. J Biol Chem. 
2003;278(45):[ZIP_CODE]- 50. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 48  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
64. Pruliere- Escabasse V, Fanen P, Dazy AC, Lechapt -Zalcman E, Rideau D, Edelman A, et al. TGF -
beta 1 downregulates CFTR expression and function  in nasal polyps of non- CF patients. Am J 
Physiol Lung Cell Mol Physiol. 2005;288(1):L77- 83. 
65. Nemzek JA, Ebong SJ, Kim J, Bolgos GL, Remick DG. Keratinocyte growth factor pretreatment is 
associated with decreased macrophage inflammatory protein- 2alpha concentrations and reduced 
neutrophil recruitment in acid aspi[INVESTIGATOR_348004]. Shock. 2002;18(6):501- 6. 
66. Yano T, Deterding RR, Simonet WS, Shannon JM, Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol. 1996;15(4):433- 42. 
67. Sugahara K, Iyama K, Kuroda MJ, Sano K. Double intratracheal instillation of keratinocyte growth 
factor prevents bleomycin- induced lung fibrosis in rats. J Pathol. 1998;186(1):90- 8. 
68. Yi ES, Salgado M, Williams S, Kim SJ, Ma sliah E, Yin S, et al. Keratinocyte growth factor 
decreases pulmonary edema, transforming growth factor -beta and platelet -derived growth factor -
BB expression, and alveolar type II cell loss in bleomycin- induced lung injury. Inflammation. 
1998;22(3):315- 25. 
69. Barazzone C, Donati YR, Rochat AF, Vesin C, Kan CD, Pache JC, et al. Keratinocyte growth factor protects alveolar epi[INVESTIGATOR_348005]- induced injury in mice. Am J 
Pathol. 1999;154(5):1479- 87. 
70. Panos RJ, Bak PM, Simonet WS, Rubin JS, Smith LJ. Intratracheal instillation of keratinocyte 
growth factor decreases hyperoxia- induced mortality in rats. J Clin Invest. 1995;96(4):2026- 33. 
71. Viget NB, Guery BP, Ader F, Neviere R, Alfandari S, Creuzy C, et al. Keratinocyte growth factor protects against Pseudomonas aeruginosa- induced lung injury. Am J Physiol Lung Cell Mol 
Physiol. 2000;279(6):L1199 -209. 
72. Wang Y, Folkesson HG, Jayr C, Ware LB, Matthay MA. Alveolar epi[INVESTIGATOR_348006]- agonist t herapy. J Appl Physiol. 
1999;87(5):1852- 60. 
73. Guery BP, Mason CM, Dobard EP, Beaucaire G, Summer WR, Nelson S. Keratinocyte growth 
factor increases transalveolar sodium reabsorption in normal and injured rat lungs. Am J Respir 
Crit Care Med. 1997;155(5):1777- 84. 
74. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin- induced acute lung injury in the ex vivo perfused human lung. 
Proc Natl Acad Sci U S A. 2009;106(38):[ZIP_CODE]- 62. 
75. Yano T, Mason RJ,  Pan T, Deterding RR, Nielsen LD, Shannon JM. KGF regulates pulmonary 
epi[INVESTIGATOR_348007]. Am J Physiol Lung Cell Mol Physiol. 2000;279(6):L1146- 58. 
76. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol. 2002;282(5):L924-40. 
77. Dada LA, Sznajder JI. Mechanisms of pulmonary edema clearance during acute hypoxemic 
respi[INVESTIGATOR_1399]: role of the Na,K -ATPase. Crit Care Med. 2003;31([ADDRESS_432411]):S248- 52. 
78. Planes C, Blot -Chabaud M, Matthay MA, Couette S, Uchida T, Clerici C. Hypoxia and beta 2-
agonists regulate cell surface expression of the epi[INVESTIGATOR_348008]. J Biol Chem. 2002;277(49):[ZIP_CODE]- 24. 
79. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin- 1 is an apoptosis survival factor for 
endothelial cells. FEBS Lett. 1999;448(2- 3):249- 53. 
80. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, et al. A ngiopoietin- 1 is 
an antipermeability and anti- inflammatory agent in vitro and targets cell junctions. Circ Res. 
2000;87(7):603- 7. 
81. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage- resistant 
blood vessels in mice transgenically  overexpressing angiopoietin -1. Science. 
1999;286(5449):2511- 4. 
82. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin- 1 reduces VEGF -stimulated 
leukocyte adhesion to endothelial cells by [CONTACT_348094]- 1, VCAM -1, and E -selectin expression. 
Circ Res. 2001;89(6):477- 9. 
83. Pi[INVESTIGATOR_348009] L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin- 1 inhibits endothelial 
permeability, neutrophil adherence and IL- 8 production. Br J Pharmacol. 2003;139(2):329- 36. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 49  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 
84. McCarter SD, Mei SH, Lai PF, Zhang QW, Parker CH, Suen RS , et al. Cell- based angiopoietin- 1 
gene therapy for acute lung injury. Am J Respir Crit Care Med. 2007;175(10):1014 -26. 
85. Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore 
epi[INVESTIGATOR_348010]-
1. J Biol Chem. 2010;285(34):[ZIP_CODE]- 22. 
86. Mason CM, Guery BP, Summer WR, Nelson S. Keratinocyte growth factor attenuates lung leak 
induced by [CONTACT_56576]- naphthylthiourea in rats. Crit Care Med. 1996;24(6):925- 31. 
87. Welsh DA, Summer WR, Dobard EP, Nelson S, Mason CM. Keratinocyte growth factor prevents ventilator -induced lung injury in an ex vivo rat model. Am J Respir Crit Care Med. 2000;162(3 Pt 
1):1081- 6. 
88. Murakami M, Nguyen LT, Zhang ZW, Moodie KL, Carmeliet P,  Stan RV, et al. The FGF system 
has a key role in regulating vascular integrity. J Clin Invest. 2008;118(10):3355- 66. 
89. Birukova AA, Alekseeva E, Mikaelyan A, Birukov KG. HGF attenuates thrombin- induced 
endothelial permeability by [CONTACT_348095]1- mediated activation of the Rac pathway and by [CONTACT_348095]1/Rac -
dependent inhibition of the Rho pathway. FASEB J. 2007;21(11):2776- 86. 
90. Singleton PA, Salgia R, Moreno- Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, et al. CD44 
regulates hepatocyte growth factor -mediated vascular integrity. Role of c -Met, Tiam1/Rac1, 
dynamin 2, and cortactin. J Biol Chem. 2007;282(42):[ZIP_CODE]- 57. 
91. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood. 2007;109(8): 3147- 51. 
92. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for 
treatment of steroid- resistant, severe, acute graft -versus -host disease: a phase II study. Lancet. 
2008;371(9624):1579- 86. 
93. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-
blind, placebo- controlled, dose- escalation study of intravenous adult human mesenchymal stem 
cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277- 86. 
94. Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. 
Cytotherapy. 2009;11(5):503- 15. 
95. Meduri GU, Chinn A. Fibroproliferation in late adult respi[INVESTIGATOR_1505]. Pathophysiology, clinical and laboratory manifestations, and response to corticosteroid rescue treatment. Chest. 1994;105([ADDRESS_432412]):127S -9S. 
96. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al. Efficacy and 
safety of corticosteroids for persistent acute respi[INVESTIGATOR_1505]. N Engl J Med. 
2006;354(16):1671- 84. 
97. Seeley E, McAuley DF, Eisner M, Miletin M, Matthay MA, Kallet RH. Predictors of mortality in acute lung injury during the era of lung protective ventilation. Thorax. 2008;63(11):994- 8. PMCID: 
2771451.  
98. Fort P, Farmer C, West erman J, Johannigman J, Beninati W, Dolan S, et al. High- frequency 
oscillatory ventilation for adult respi[INVESTIGATOR_1505]--a pi[INVESTIGATOR_799]. Crit Care Med. 1997;25(6):937- 47. 
99. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis -related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf 
of the Working Group on Sepsis -Related Problems of the European Society of Intensive Care 
Medicine. Intensive Care Med. 1996;22(7):707- 10. 
100. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, et al. A trial of 
antioxidants N -acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. 
Chest. 1997;112(1):164- 72. 
101. Office for Human Research Protections. Guidance on Reviewing and Reporting 
Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events. Department 
of Health and Human Services;  [January 15, 2007; cited 2008]; Available from: 
http://ww w.hhs.gov/ohrp/policy/AdvEvntGuid.htm . 
  
Date:  February 17, [ADDRESS_432413] (AUDIT)  
E. Ventilator Management  
F. Clinical Cell Wash Protocol  
G. Human Mesenchymal Stem Cell Infusion Procedure  
H. Guidelines for Symptom Management During hMSCs Infusion 
I. Mini-Bronchoalveolar Lavage Procedure 
J. Investigational Product Infusion Protocol for Phase 2  
K. Barotrauma  
 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD          Page 51  
University of [LOCATION_004], San Francisco                                                             Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
                                                                                      Appendix A:  Time- Events Schedule  
 
Appendix A : Time-Events Schedule   
Measurement/Event  Day 0 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 28 6m 12m Prior to 
randomization  
Prior to MSC 
infusion& 
During and 
after  
MSC infusion              
Demographics, History & Physical, Height, Weight  X                    
Etiology of ARDS, site of sepsis if septic etiology X                    
HCG (in females  of childbearing age ) X                    
Alcohol Use Disorders Identification Test (AUDIT)  X                    
APACHE III Score C X                    
Vital Signs (HR, SBP, DBP, MAP, Temp oC) *$ X X X X X X X X X X X X X X X X X    
Central Venous Pressure *  A A A A A A A A A A A A A A A A A    
Fluids (In and Out) *  X X X X X X X X X X           
Modified Brussels Score and Brussels Organ Dysfunction FailureB ~ X   X X X X X X X X X X X X X X    
Sequential Organ Failure Score  X   X X X    X       X    
Ventilator Parameters (including FiO 2) *#$ X X X X X X X X X X           
Arterial Blood Gases (PaO 2, PaCO 2, pH) and SpO 2D X X X A A X A A A A           
CreatinineE X   A A X A A A X A A A A A A X A   
Chest X -ray (# quadrants for lung injury score)  X   A A X A A A A A A A        
Record vasopressors or inotropes * (Y/N) $ X X X X X X X X X X X X X X X X X    
Suspected or known site of infection  X         X       X    
Total bilirubin, ALT, plateletsF X     X    X       X    
Blood and urine for cytokines, mediators and markers of inflammationG  X  X X X X    X           
Blood cell pellet for DNA banking (if consent obtained)  X                    
Mini-BAL (Phase 2 only)      X                
Vital Status §                   X X X 
Need for, timing and duration of dialysis                  X X X 
X=Required;   A=When available;   C=Labs not available in the [ADDRESS_432414] be obtained;   *= Data gathered at times indicated or until [ADDRESS_432415]  
B=Record clinically available creatinine, platelets, bilirubin, SBP and vasopressor use;  ~=Data gathered on days 0- 28 or until d/c from study hospi[INVESTIGATOR_307];  #=Measure during reference period (0600- 1000); other values may be obtained closest 
to 0800 on the specified calendar date;  §=Measure at 28 days, 6 months and 12 months; the 12 month follow up visit will be an inperson visit with a focused history and physical examination  
D= ABG mandatory at  the following timepoints: within 6 hours of randomization, prior to the start of the infusion (during the final 30 minutes of th e baseline stability period); within 15 minutes of the end of MSC infusion (~ 1 hour ) and 4 hour s 
after the initiation of the infusion;  E=Record clinically available creatinine in the [ADDRESS_432416] 
value during the entire hospi[INVESTIGATOR_348011] ; F=Data required prior to   randomization,   day 3  (+/-1 day) , day 7 (+/ -1 day) and day 14 (+/ -1 day);  $=Data recorded every [ADDRESS_432417] two hours during “stable baseline” 
period and until the initiation of study drug infusion,  every 15 minutes for the duration of the infusion and every hour  until 6 hours from the initiation of study drug infus ion;  G= Blood and urine specimens are required before the hMSC infusion, 
at 6 hours and 1, 2, 3, 7 days (+/ - 2 day) after the initiation of the study product infusion.  
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 52  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix B: Lung Injury Score 
 
Appendix B: Lung Injury Score  
 
The Lung Injury Score  (Murray JF et al., 1988) is a validated  4-point score based on chest 
radiograph findings, PaO2/FiO2 ratio, PEEP and compliance. Scoring is performed for each 
individual component, and the score is the average of the 4 components. 
 
Lung Injury Scoring  Value Score 
CXR (# of quadrants with infiltrates)    
   
PaO2/FiO2    
   
PEEP   
   
Compliance    
   
Total score    
Actual score (total points/4)   
 
 
Scoring:  
 1 points  2 points  3 points  4 points  
CXR (#  of quadrants with 
infiltrates)   2 quadrants  3 quadrants  4 quadrants  
PaO2/FiO2  225-299 175-224 100- 174 < 100  
PEEP  6-8 9-11 12-14 ≥ 15 
Compliance  60-79 40-59 20-39 ≤ 19 
 
Static compliance can be calculated as: Tidal volume/(Plateau pressure – PEEP)  
   
 
Reference: Murray  JF, Matthay  MA, Luce JM,  et al. An expanded definition of  the adult  respi[INVESTIGATOR_212284].  Am Rev Respir  Dis 1988;138:720 –3; erratum  1989;139:1065.
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 53  
University of [LOCATION_004], San Franc isco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix C: De- identified Data Elements  
 
Appendix C: De -identified Data Elements for Screened, Non- enrolled Subjects  
 
1. Was onset of ARDS acute? 
2. Did frontal CXR show bilateral infiltrates consistent with pulmonary edema?  
3. Number of quadrants with opacities? 
4. Is patient intubated?  
5. PaO2 
6. FiO2 
7. Was there evidence of left atrial hypertension?  
8. Month of the year that patient met screening criteria  
9. Gender 
10. Ethnicity 
11. Age (if age >89, 89 will be entered for age) 
12. Patient location (e.g. MICU, SICU, etc.) and if regularly screened  
13. Reason(s) patient excluded from study 
14. If not excluded, not enrolled, why? 
15. Lung injury category (e.g. sepsis, pneumonia) 
 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 54  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix D: Alcohol Use Disorder Identification Test  
 
Appendix D: Alcohol Use Disorder Identification Test (AUDIT) 
 
The Alcohol Consumption Questionnaire is important to administer because there is a common 
association between alcohol abuse and ARDS (Moss M et al., 1996).  It will be important to have 
this information for a subgroup analysis.  
 
 
Reference: Moss M, Bucher B, Moore FA, et al.  The role of chronic alcohol abuse in the development of 
acute respi[INVESTIGATOR_348012]. JAMA 1996; 275:50- 54 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 55  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix E: Ventilator Management  
 
Appendix E: Ventilator Management  
 
1.  Ventilator Management  
A modified, simplified version of the ARDS Network lung protective lower tidal volume 
strategy will be used in this trial.  This strategy, which was associated with low mortality rates in three previous ARDS Network trials (ARMA, ALVEOLI, and FACTT), will ensure that study 
subjects receive the beneficial effects of lung protection while participating in this trial (The 
Acute Respi[INVESTIGATOR_196700]  , and Brower et al., 2004) .  ARDS  Network 
personnel have substantial experience in the applicati on of this protocol from the three 
completed trials noted above.  
1. Any mode of ventilation capable of delivering the prescribed tidal volume (V
T, 6ml/kg 
predicted body weight, +/- 2ml/kg) may be used, provided the V T target is monitored and 
adjusted appropr iately.  If airway pressure release ventilation (APRV) is used, tidal 
volume is defined as the sum of the volume that results from the ventilator pressure-release and an estimation of the average spontaneous V
T.   
2. VT Goal:  6 ml / kg predicted body weight.  
3. Predicted body weight (PBW) is calculated from age, gender, and height (heel to crown) according to the following equations: 
a. Males: PBW (kg) = 50 + 2.3 [height (inches) – 60] 
b. Females:  PBW (kg) = 45.5 + 2.3 [height (inches) – 60] 
4. Measure and record inspi[INVESTIGATOR_347988] (Pplat) according to ICU routine (at least 
every four hours and after changes in V
T and PEEP recommended) 
5. If Pplat > 30 cm H 2O, reduce V T to 5 ml / kg and then to 4 ml / kg PBW if necessary to 
decrease Pplat to ≤ 30 cm H 2O. 
6. If VT < 6 ml/kg PBW and Pplat < 25 cm H 2O, raise V T by 1 ml / kg PBW to a maximum 
of 6 ml/kg. 
7. If “severe dyspnea" (more than [ADDRESS_432418] pressure remains at or below PEEP level during inspi[INVESTIGATOR_1516]), then raise V
T to 7 or 8 ml/kg PBW if Pplat 
remains below 30 cm H 2O.  If Pplat exceeds 30 cm H 2O with V T of 7 or 8 ml/kg PBW, 
then revert to lower V T and consider more sedation. 
8. If pH < 7.15, V T may be raised and Pplat limit suspended (not required). 
9. Oxygenation target:  55 mm Hg < PaO 2 < 80 mm Hg or 88% < SpO 2 < 95%.  When both 
PaO2 and SpO 2 are available simultaneously, the PaO 2 criterion will take precedence.   
10. Minimum PEEP = [ADDRESS_432419] within 5 minutes if there are consistent measurements 
below the oxygenation target range 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 56  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix E: Ventilator Management  
 
12. Adjust F IO2 or PEEP downward within 30 minutes if there are consistent measurements 
above the oxygenation target range.   
13. There are no requirements for maintaining a specific PEEP to F IO2 ratio.  The lower 
PEEP/higher F IO2 table represents a consensus approach developed by [CONTACT_348096] 1995.  The higher PEEP/lower F IO2 table (ALVEOLI) yielded equivalent 
results in a randomized trial (Brower et al., 2004)  and would be acceptable and perhaps 
preferable in patients who appear to respond with a substantial increase in arterial oxygenation in the transition from lower to higher PEEP. 
 
 
Lower PEEP/Higher F
IO2 Treatment Group  
 
 
Higher PEEP/Lower F IO2 Study Group 
 
Note: Levels of PEEP in these F IO2/ PEEP tables represent levels set on the ventilator, not 
levels of total- PEEP, auto -PEEP, or intrinsic- PEEP. 
 
14. No specific rules for respi[INVESTIGATOR_697]. It is recommended that the respi[INVESTIGATOR_348013] a maximum set rate of 35 if pH < 7.30. 
15. No specific rules about I: E.  It is recommended that duration of Inspi[INVESTIGATOR_196674] ≤ duration 
of Expi[INVESTIGATOR_1516]. 
16. Bicarbonate is allowed (neither encouraged nor discouraged) if pH < 7.30. 
17. Changes in more than one ventilator setting driven by [CONTACT_196759] 2, pH, and 
Pplat may be performed simultaneously, if necessary. 
 
 
References: 
The Acute Respi[INVESTIGATOR_196700]. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respi[INVESTIGATOR_1505]. The Acute Respi[INVESTIGATOR_196700]. 2000; 342:1301-1308. 
 
Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end- expi[INVESTIGATOR_348014]. N Engl J Med 2004; 
351:327-336.  FIO2 .30 .40 .40 .50 .50 .60 .70 .70 .70 .80  .90 .90 .90 1.0 
PEEP 5  5   8   8  10 10 10 12 14 14 14 16 18 18-24 
FIO2 .30 .30 .30 .30 .30 .40 .40 .50 .50 .50 – .80 .80 .90 1.0 1.0 
PEEP 5 8 10 12 14 14 16 16 18 20 22 22 22 24 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 57  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix E: Ventilator Management  
 
2.  Weaning  
Commencement of Weaning (applicable to patients ventilated invasively or non-invasively): 
Patients will be assessed for the following weaning readiness criteria each day between [ADDRESS_432420] 12 hours since enrollment in the trial 
2. F
IO2 ≤ 0.40 and PEEP ≤  8 cm H2O or F IO2 ≤ 0.50 and PEEP = 5 cm H 2O 
3. Values of both PEEP and F IO2 ≤ values from previous day (comparing Reference 
Measurement values, section 6.3) 
4. Not receiving neuromuscular blocking agents and without neuromuscular blockade 
5. Patient exhibiting inspi[INVESTIGATOR_91401]. If no efforts are evident at baseline, ventilator set 
rate will be decreased to 50% of baseline level for up to [ADDRESS_432421] inspi[INVESTIGATOR_91401]. 
6. Systolic arterial pressure ≥ 90 mm Hg without vasopressor support ( ≤ 5 mcg/kg/min 
dopamine or dobutamine will not be considered a vasopressor) 
 
Spontaneous Breathing Trial Procedure and Assessment for Unassisted Breathing: 
If criteria 1 -6 above are met, then initiate a trial of up to 120 minutes of spontaneous 
breathing with F IO2 < 0.5 using any of the following approaches: 
1. Pressure support (PS) < 5 cm H 2O, PEEP < 5 cm H 2O  
2. CPAP < 5 cm H 2O  
3. T-pi[INVESTIGATOR_13959]  
4. Tracheostomy mask  
 
The clinical team may decide to change mode during spontaneous breathing (PS = 5, CPAP, tracheostomy mask, or T- pi[INVESTIGATOR_13959]) at any time during the spontaneous breathing trial.  
 
Monitor for tolerance using the following: 
1. SpO
2 ≥ 90% and / or PaO 2 ≥ 60 mm Hg 
2. Mean spontaneous tidal volume ≥  4 ml/kg PBW (if measured)  
3. Respi[INVESTIGATOR_13581] ≤ 35 / min 
4. pH ≥ 7.30 (if measured) 
5. No respi[INVESTIGATOR_1506] (defined as 2 or more of the following): 
a. Heart rate ≥ 120% of the 0600 rate ( ≤ 5 min at > 120% may be tolerated) 
b. Marked use of accessory muscles  
c. Abdominal paradox 
d. Diaphoresis 
e. Marked subjective dyspnea 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 58  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix E: Ventilator Management  
 
If any of the goals a -e are not met, revert to previous ventilator settings or to PS greater than 
or equal to 10 cm H 2O with Positive End -expi[INVESTIGATOR_196676] F IO2 = previous settings 
and reassess for weaning the next morning.  The patient will be reassessed for weaning 
(Section E2) the following day.  
Decision to remove ventilatory support: 
If tolerance criteria for spontaneous breathing trial (a- e above) are met for at least 30 
minutes, the clinical team may decide to discontinue mechanical ventilation. However, the spontaneous breathing trial can continue for up to120 minutes if tolerance remains in question.   
3.  Definition of Unassisted Breathing  
1. Spontaneously breathing with face mask, nasal prong oxygen, or room air, OR 
2. T-tube breathing, OR 
3. Tracheostomy mask breathing, OR 
4. CPAP ≤ [ADDRESS_432422] completed the study ventilator procedures if any of the following conditions occur: 
1. Death 
2. Hospi[INVESTIGATOR_2345] 
3. Alive 28 days after enrollment 
 
If a patient requires positive pressure ventilation after a period of unassisted breathing, the study ventilator procedures will resume unless the patient was discharged from the hospi[INVESTIGATOR_6879] > 28 days elapsed since enrollment. 
 
6.  Removal from the Ventilator Management Protocol  
Patients may be removed from the 6 ml/kg PBW tidal volume ventilation requirement if they 
develop neurologic conditions where hypercapnia would be contraindicated (e.g., intracranial bleeding, GCS < 8, cerebra l edema, mass effect [midline shift on CT scan], papi[INVESTIGATOR_044], 
intracranial pressure monitoring, fixed pupi[INVESTIGATOR_8324]). 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 59  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix F: Clinical Cell Wash Protocol  
 
Appendix F: Clinical Cell Wash Protocol  
 
Allogeneic Bone Marrow -derived Human Mesenchymal Stem Cells (hMSCs)  
Clinical Cell Wash Protocol  
 
 
Document Date:  
21 January 2014 
 
To be used in support of  
Protocol Title:  A Phase 1/ 2, Randomized, Double -blind, Placebo -controlled, 
Multi-center Clinical Trial of Allogeneic Bone Marrow -derived 
Human Mesenchymal Stem Cells for the Treatment of Acute 
Respi[INVESTIGATOR_348015]:  UCSF-hMSC-ARDS-P1P2-06 
Sponsor-
Investigator:  Michael A. Matthay, MD  
University of [LOCATION_004], San Francisco  
 
 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 60  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix F: Clinical Cell Wash Protocol  
 
1.Background  
Allogeneic, bone marrow -derived human mesenchymal stem  cells (hMSCs) will be received 
frozen from:  
University of Minnesota Medical Center (UMMC)  
Clinical Cell Therapy Laboratory  
Molecular and Cellular Therapeutics (MCT)  
[ADDRESS_432423] is  cryopreserved for long-term storage. The cryopreserved hMSCs are 
formulated in DMSO (10%), human serum albumin (5%) and Plasma -Lyte A (30%).   
Once received at the clinical site, the hMSCs will be stored under controlled conditions in liquid 
nitrogen tanks in the Clinical Bone Marrow Transplant Facility  (or equivalent).  
Just prior to use, the cellular product will be thawed, washed and prepared for intravenous 
administration  in the Clinical Bone Marrow Transplant Facility  (or equivalent) by [CONTACT_348097].  
→ The hMSCs administration must be completed within 4 hours of the start of the thaw procedure. The hMSCs will be administered over 60-80 minutes.   
 
→ Each Clinical Bone Marrow Transplant Facility (or equivalent) will develop their own site-
specific Standard Operating Procedure in support of this protocol. The laboratory- specific 
standard operating procedure at each site will be reviewed by [CONTACT_348098]. To assist with this process, the Coordinating Center will share the SOP de veloped by [CONTACT_348099].  
 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 61  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix F: Clinical Cell Wash Protocol  
 
[ADDRESS_432424] operating procedure. These will include but are not limited to: 
 
Reagents:  
Plasma-Lyte A (Baxter) for cell wash and resuspension  
Trypan blue for cell counts  
Supplies: 
 Sterile cell transfer pack, 300 mL  
 Blood culture bottles for sterility testing  
 Equipment: 
  Balance 
  Centrifuge   Heat sealer  
  Hemostat  
  Hematocytometer  
  Laminar Flow Hood   Microscope   Plasma Expressor  
  Water Bath  
 
 
   
    
    
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 62  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix F: Clinical Cell Wash Protocol  
 
[ADDRESS_432425] patient.  
3.1.2 Bring water bath to 37°C. 
3.1.3 Turn on and c lean biocontainment hood before use. 
3.1.4 Turn on centrifuge. Set to refrigerated temperature of 2-5°C and spin for 15 minutes at 
400g. Verify temperature and rpms during initial use.  
3.1.5 All calculations will be done on a hMSC Calculation Worksheet, which will be retained by [CONTACT_348100] a source document. 
 3.2 Thawing of hMSCs  
3.2.1  Locate appropriate bags of hMSCs (stored in liquid nitrogen in the Clinical Bone Marrow 
Transplant F acility).  
NOTE:  Prior to thawing, laboratory staff must calculate the number of cells 
needed for the study subject based on predicted body weight, and they must determine the number of cell bags they will need to thaw to have th is dose of 
cells available. No more than 1 x 10
9 cells (100 kg x 10 x 106 cells/kg) will be 
administered to any subject.  
At the same time, the Clinical Bone Marrow Transplant Facility will calculate the 
amount of endotoxin present in the original hMSC product based on the lot release information supplied by [CONTACT_137025]. The acceptance limit is <5.0 EU/Kg.   
3.2.2 Cells should not be thawed until the laboratory has staff available to start the wash procedure immediately after the thaw procedure is complete. Thaw time, time wash was completed, and infusion start/stop times will be recorded. 
3.2.[ADDRESS_432426] protocol of the local Clinical Bone 
Marrow Transplant Facility  (or equivalent). This protocol will be reviewed by [CONTACT_348101].  
3.3.2 The general principles of the wash procedure are as follows: 
(1) Cells should be transferred from the original bag to a 300 mL transfer pack for centrifugation under sterile conditions, along with the appropriate volume of Plasma-
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 63  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix F: Clinical Cell Wash Protocol  
 
Lyte A for the wash . If multiple bags of cells are thawed, pool cells prior to the wash 
procedure. 
(2) Cells should be placed in the centrifuge and centrifuged 400g for 1 5 minutes at 2-5˚C.    
(3) Supernatant should be removed aseptically using a plasma expressor. The laboratory 
should determine ahead of time what the maximum volume of supernatant that will 
be removed is and this should be part of the standard operating procedure developed 
by [CONTACT_25699].  
(4) Cells should be resuspended in Plasma- Lyte A to a pro duct of 100 mL 
(5) Remove a 5.[ADDRESS_432427]-Wash/Reconstituted Cel ls to use for the 
following tests: 
• 0.5 mL for total cell count; cells should be counted undiluted, 1:5 and 1:10 
• 0.5 mL for viability testing  by [CONTACT_348102]  
• [ADDRESS_432428]-Wash/Reconstituted Cells  to a final volume of 
100 mL. 
3.3.4 Clinical Bone Marrow Transplant F acility staff should complete the “BMT Lab” section 
of the Infusion Form. This will include product thaw date/time, expi[INVESTIGATOR_320]/time, and 
product identification number. 
[ADDRESS_432429] be completed within 4 hours of the start of the thaw procedure. The hMSCs will be administered over 60-80 minutes.   
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 64  
University of Califo rnia, San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix G: hMSCs Infusion Procedure  
 
Appendix G: Human Mesenchymal Stem Cell Infusion Procedure 
 
BACKGROUND:  Human mesenchymal stem cells (hMSCs) are being administered here as a 
novel therapy for the acute respi[INVESTIGATOR_1505]. Several factors are essential to the safe 
administration of hMSCs. They include accurate identification of the donor, the recipi[INVESTIGATOR_841]; the product; and the cell dose. Therapi[INVESTIGATOR_348016]. In addition, recognition and management of the potential side effects associated with hMSC infusion are also important.  Toxicity from DMSO used to protect hMSCs during cryo- preservation is not a majo r 
concern since the hMSCs will be washed after the thaw and prior to infusion; renal toxicity from red blood cell disruption during the freeze/thaw procedure is also not a concern since these cells are cultured prior to cryopreservation.  Each study site w ill develop their own site -specific Standard Operating Procedure in support of 
this protocol. The site- specific standard operating procedure will be reviewed by [CONTACT_348103].  
 
1.  OBJECTIVE:  
1.1 To ensure the safe and effective infusion of clinical grade allogeneic bone marrow -
derived human mesenchymal stem cells (hMSCs) .  
1.2 To ensure the administration of the total prescribed hMSC dose  
 
2. MATERIALS/EQUIPMENT  
2.[ADDRESS_432430] blood filter tubing Y set (170-260 micron filter): At UCSF Medical Center, 
this is Baxter 4C6772 
2.[ADDRESS_432431] luer stopcock  
2.5 Large luer lock syringe (10 mL or greater) 
 3. POLICIES  
3.[ADDRESS_432432] initiate and be present for the entire duration of the hMSC infusion (or placebo in Phase 2). 
3.[ADDRESS_432433] hMSCs . In the event of an adverse reaction terminating the infusion, 
return any un-transfused hMSCs to the BMT laboratory immediately. 
3.5 No prophylactic pre-medications (e.g. acetaminophen or diphenhydramine) will be 
administered prior to the hMSCs .  If such medications are ordered by [CONTACT_348104], however, their use does not preclude proceeding with the infusion. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 65  
University of Califo rnia, San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix G: hMSCs Infusion Procedure  
 
3.6 The following medications should be immediately available at the patient’s bedside 
during the infusion and the post-infusion monitoring period: epi[INVESTIGATOR_238] 1 mg for intravenous administration, hydrocortisone 100 mg for intravenous administration, and diphenhydramine 50 mg for intravenous administration. 
3.7 hMSCs can be infused via peripheral or central venous access.  If peripheral, the IV should preferably be 18 gauge, but no smaller than 20 gauge. 
3.8 Ideally a separate port or line shoul d be used for the hMSC infusion. The hMSC 
infusion should not be “pi[INVESTIGATOR_348017]” into a medication line. If absolutely necessary, a stopcock can be used at the lumen connection to create a separate, dedicated line for the hMSC infusion. Avoid administration with dextrose containing solutions; Normal saline, Plasmalyte, and Lactated Ringers are acceptable.  
3.9 Dialysis Patients:  Patients receiving intermittent dialysis may be dialyzed prior to 
hMSC infusion, but should not be dialyzed until 24 hours or more after the hMSC infusion if possible. Continuous renal replacement therapy will be allowed to continue during the hMSC or placebo infusion. 
3.10 Prone positioning : Patients must be in the supi[INVESTIGATOR_348018]-infusion baseline 
stability period, and must remain in the supi[INVESTIGATOR_348019].  The patient should also remain supi[INVESTIGATOR_1919] [ADDRESS_432434] precautions and aseptic technique at all times.  
3.12 Verify patient’s identity per National Patient Safety Goals (two identifiers). (At UCSF Medical Center, the Department of Nursing Blood and Blood Components Administration Procedure should be followed). 
3.13 Monitor the patient for reaction to the hMSC infusion during administration (see attached potential side effects).  
 
4. PROCEDURE  
4.1 Study Physician to write order for cell infusion. This order also confirms the date, and 
time of the hMSC infusion. No hMS Cs are to be thawed, processed, or released from 
the BMT laboratory without this order. (At UCSF Medical Center: Fax infusion order 
to BMT Lab, fax #353-1227.  Confirm infusion time with BMT laboratory at 353-1789). 
4.2 Set up IV tubing as follows: normal saline bag, “Y -set” standard blood filter tubing (170 - 
260 micron filter tubing, for example Baxter 4C6772) with one 3- way luer-lock 
stopcock at the end. Saline prime the blood filter tubing setup. Do NOT use bifuse tubing. DO NOT INFUSE THROUGH A NEEDLELESS CAP.  
4.3 hMSCs will be administered as 100 mL in a 300 mL transfer bag; in Phase 2 this bag will be covered with aluminum foil to blind investigators to the content. In addition, in phase 2, the BMT laboratory will label both the transfer bag and the aluminum foil cover with the patient identifiers.  
4.4 The Study Physician will: 
• Confirm that the patient has met criteria to receive the hMSC infusion: the 2 hour stable baseline period has been achieved, and the PaO2/FiO2 ratio on a blood gas 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 66  
University of Califo rnia, San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix G: hMSCs Infusion Procedure  
 
obtained during the last 30 minutes of the stable baseline prior to infusion does not 
exceed 300. If the PaO2/FiO2 ratio is greater than 300, the patient is no longer eligible to receive hMSCs.  
• Follow National Patient Safety Goals to identify the patient (two identifier s).  (At 
UCSF Medical Center: Verify patient identification per Department of Nursing Blood and Blood Components Administration Procedure). 
• Verify that the signed consent is in the patient’s medical record.  
• Review the infusion order. 
• Double-check the information on the hMSC bag with the bedside RN for the 
following:   
• Recipi[INVESTIGATOR_348020]/ID#  
• Recipi[INVESTIGATOR_348021]  
• Product Unique Identifier (DIN) 
• Product Proper Name 
[CONTACT_348115] a second person should 
compare it wi th the information on the paperwork and patient identification band. One 
of these two individuals should be a study investigator.  
• Prior to infusion, the study physician should ensure that the following medications 
are available at the patient’s bedside:  
• Epi[INVESTIGATOR_238]: 1 mg 
• Hydrocortisone: 100 mg 
• Benadryl: 50 mg 
4.5 The study physician will be present for and will directly oversee the entire infusion 
procedure: 
• Spi[INVESTIGATOR_348022] 
• The cells can be spi[INVESTIGATOR_348023]. There is no need to wait for the cells to come to room temperature.  
• Attach the primed filter tubing  with the three -way stopcock to the intravenous line 
through which the hMSCs are to be infused  
• Confirm that all IV connections are secure and that the infusion lines from the MSC 
to the patient are visible.  
• Document the start date and time of the hMSC infusion on the hMSC Infusion Record. 
4.6 Start the infusion: 
• At each center, the priming volume of the filter set must be measured prior to 
enrollment of the first study patient:  
o For example, for Baxter 4C6772, the priming volume ranges from 80- 100 mL, 
depending on the drip chamber prime volume 
o The drip chamber should not be primed to “full” since the infusion rate will be set based on the number of drops/minute that are used 
• Run HALF of the estimated priming volume in over 10-15 minutes, checking the 
drop rate at the start of the infusion and approximately 5 minutes later. The drop 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 67  
University of Califo rnia, San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix G: hMSCs Infusion Procedure  
 
rate should be checked by [CONTACT_348105] 30 seconds and 
calculating the number of drops/minute. 
• Run the remain HALF of the estimated priming volume and the cells in  over 50-60 
minutes, checking the drop rate at the start of the infusion, approximately 5 minutes after the start, and periodically throughout the infusion 
• For the Baxter 4C6772 filter set: 
o Infuse 40 mL over 10- 15 minutes, calculating the drop rate/minute   
 The # drops/mL for this priming set per the manufacturer is approximately 15 
 Therefore 40 mL = 40 mL * 15 drop/mL = 600 drops 
 600 drops/10 minutes = 60 drops/minute = 30 drops/30 seconds 
 600 drops/15 minutes = 40 drops/minute = 20 drops/30 seconds 
 Therefore the target infusion rate is 25-30 drops/[ADDRESS_432435] 10 minutes  of the infusion  
o For the second half of the prime volume and 100 mL of cells , 
 (40 mL prime + 100 mL cell volume) * 15 drops/mL = 2100 drops 
 2100 drops/50 minutes = 42 drops/minute = 21 drops/30 seconds  
 2100 drops/60 minutes = 35 drops/minute = 17.5 drops/30 seconds  
 Therefore the target infusion rate is 18-20 drops/30 seconds for 
the next 50-60 minutes  
4.7 Do not run normal saline concurrently wi th the cells.  
4.8 When the cell bag is empty, proceed to the RINSE AND FLUSH PROCEDURES  
(4.12) to rinse the bag and flush the line.  
4.[ADDRESS_432436] 
stop-cock and push hMSCs through line slowly (2- 5 mL/min) via a syringe.  
4.[ADDRESS_432437] original filter set for the bone marrow transplant laboratory. Document if clumpi[INVESTIGATOR_348024]. 
4.11 Monitoring:  
• Blood pressure, heart rate and oxygen saturation will be continuously monitored for 
the duration of the infusion and documented every 15 minutes during the infusion. 
• An arterial blood gas will be obtained within the 30 minutes prior to the start of the infusion (DURING the baseline stability period) and within 15 minutes of the end 
of the infusion. If the paO2/FiO2 ratio on the blood gas obtained during the baseline stability period is greater than 300, the patient should NOT receive hMSCs. 
• See Appendix H for potential side effects of transfusion. Monitor periodically 
during the infusion for these side effects.  If the patient experiences significant side effects, consider pausing or stoppi[INVESTIGATOR_348025]. 
4.12 RINSE AND FLUSH PROCEDURE: Approximately [ADDRESS_432438] been 
rinsed from the bag and infused through the priming setup. The target infusion rate 
during the rinse and flush procedure is increased, as the pat ient has already 
received a large portion of the infusion, and the rinse is expected to be more dilute.  
• At the end of the infusion, rinse the hMSC bag with normal saline using this 
protocol. To do this: (1) Clamp the hMSC line to the patient (2) Unclamp t he saline 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 68  
University of Califo rnia, San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix G: hMSCs Infusion Procedure  
 
line and lower the hMSC bag to allow for saline to enter the hMSC bag; (3) After a 
small amount of saline (approximately 20 mL) has entered the hMSC bag, reclamp the saline line; (4) Swirl the saline in the hMSC bag until the sides of the bag are  
clear of cells (in Phase [ADDRESS_432439] remain blinded to treatment); (5) Re -hang the hMSC bag, 
then open the line and infuse the saline rinse from the hMSC bag into the patient until the b ag is empty; (6) Finally, allow 80 mL (priming volume) of saline to run 
through the filter to flush the remaining rinse volume into the patient.  The rinse 
and flush volume should be infused over approximately 20 minutes:  
 (20 mL rinse + 80 mL flush) * 15 drops/mL = 1500 drops 
 1500 drops/20 minutes = 75 drops/minute = 32.5 drops/30 seconds  
 Therefore the target infusion rate for the rinse and flush is approximately 30 drops/30 seconds for 20 minutes  
• If cell clumps are still seen in the filter, clamp the hMSC line and unclamp the saline 
line. Attach a large syringe to the stopcock nearest the patient. Flip the stopcock to allow for saline to be drawn through the filter and tubing into the syringe. Aspi[INVESTIGATOR_348026] (the a spi[INVESTIGATOR_348027] a filter flush). When the syringe is full, turn the stopcock (open to the patient’s IV) to allow for the contents of the syringe to be injected into the patient. Empty the syringe  slowly (2 -5mL/min) . Repeat this process until the filter is clear of 
cells.  
4.13 hMSC bags and tubing should be returned to the BMT laboratory 
4.14 Obtain and document vital signs at completion of infusion. 
 
 
5. Documentation:  
5.[ADDRESS_432440] should be placed in the patient’s paper medical record or scanned into the electronic medical record; a hard copy must also be sent to the local BMT lab and to the University of Minnesota.  
5.2 The study investigator will inform the bedside RN of the total volume (hMSC and saline 
wash) used during the infusion procedure so this can be documented in the patient’s medical record.  
5.[ADDRESS_432441], MSC dose infused, and any complications or adverse reactions.
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 69  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix H: Symptom Management During Infusion Guidelines  
 
Appendix H: Guidelines for Symptom Management During hMSCs Infusion  
 
Adverse Reactions  Signs and Symptoms  Management  
Hypersensitivity  
 
Hypersensitivity to allogeneic plasma proteins.  • dyspnea  
• hypotension  
• fever 
• urticaria  
• tachycardia  
• hypoxemia  • Pause MSC infusion  
• Check vital signs and O 2 saturation  
• Hydrocortisone 1mg/kg IV  
• If still symptomatic after hydrocortisone, then diphenhydramine 25- 50 mg IV
 
• Increase supplemental O 2 if O 2 saturation is 
<93% and/or dyspnea  
• Resume MSC infusion after reasonable 
resolution of signs and symptoms.  
Leukoagglutination  
 
Because some leukocytes 
may be present in the MSC 
preparation (although MSC purity will typi[INVESTIGATOR_175640] >95%), leukoagglutination symptoms 
may occur.  • cough  
• “tickle in throat”  
• dyspnea  
• hypoxemia  
• chest pressure  • Pause MSC infusion.  
• Check vital signs and O 2 saturation  
• Increase supplemental O 2 if O 2 saturation is 
<93% and/or dyspnea.  
• Resume MSC infusion after reasonable resolution of signs and symptoms.
 
Volume Overload  
 
Although the volume of the 
MSC will be set at 100 ml total, pulmonary edema may occur in this population. This can occur with or without 
concurrent cardiac 
dysfunction.  
 
 • dyspnea  
• hypoxemia  
• frothy, clear or pi[INVESTIGATOR_348028]
 
• tachycardia  
• lack of fever  
• distended neck 
veins  • Pause MSC infusion.  
• Check vital signs and O 2 saturation.  
• Increase supplemental O 2 if O 2 saturation is 
<93% and/or patient is dyspneic.  
• Furosemide (≥ 10 mg IV)  
• Resume MSC infusion after reasonable 
reduction of signs and symptoms.  
Transfusion Incompatibility  
 The infusion of allogeneic 
MSC can be incompatible 
based on the presence of allo-antibodies in the donor 
and/or recipi[INVESTIGATOR_348029]. Transfusion incompatibility reactions are usually 
symptomatic and occasionally 
life-threatening.  
 • fever 
• hypotension  
• dyspnea  
• low back pain  
• dark urine  
• drop in blood 
hemoglobin  
• disseminated-
intravascular 
coagulation  • Stop MSC infusion.  
• Check vital signs and O 2 saturation.  
• IV fluid resuscitation immediately if 
hypotensive.  
• Forced diuresis and urinary alkalinization 
with IV D5W + 2 amps/l sodium bicarbonate.  
• Send recipi[INVESTIGATOR_348030] a “transfusion 
reaction analysis” to the blood bank.  
• Consider mannitol 25 gm IV if suspi[INVESTIGATOR_1884] a transfusion ABO incompatibility reaction is high.
 
• Consider blood cultures (and culture of the MSC product) followed by [CONTACT_348106]-bacterial antibiotics.
 
• The attending BMT physician will be informed of the epi[INVESTIGATOR_348031].
 
• If the MSC infusion is aborted, the balance of 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 70  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix H: Symptom Management During Infusion Guidelines  
 
Adverse Reactions  Signs and Symptoms  Management  
the MSC product will be quarantined in the 
BMT laboratory refrigerator for possible 
additional analysis.  
Reactions to 
Cryopreservatives (e.g. 
DMSO)  
 
DMSO is added to all MSC 
products being cryopreserved to protect the MSC from 
hypothermal damage.  The cell product will be washed to minimize the infusion of 
DMSO, but the infusion of 
DMSO has side effects and consequences that study personnel need to be aware of • metallic/garlic taste
 
• nausea/emesis  
• flushing of face 
• intestinal cramps  
• acute hypertension
 
• bradycardia (first, second, or third degree 
atrioventricular 
block on electrocardiogram)
 • Pause MSC infusion.  
• Check vital signs and O 2 saturation.  
• Administer additional anti -emetics if 
appropriate.  
• If bradycardia, perform an electrocardiogram. If patient is asymptomatic with first or second degree atrio- ventricular block on EKG, 
resume MSC infusion.  If symptomatic, stop infusion and administer atropi[INVESTIGATOR_050] 0.5 -1mg. 
 
• If bradycardia is present and 
electrocardiogram shows third degree atrio-
ventricular block, consider placement of a temporary pacemaker.  Consult Cardiology.
 
• Infuse remainder of previously non- thawed 
MSC after reasonable resolution of the signs and symptoms of an acute DMSO reaction 
and acquisition of hemodynamic stability.  
Infection/Endotoxemia  
 The infusion of infected MSC products is usually fatal.  A rapid response to the acute 
adverse signs/symptoms of 
the infusion of the infected MSC may be life- saving. • hypotension  
• fever 
• oliguria/anuria  
• tachycardia  
• dyspnea/ 
hypoxemia  
• disseminated 
intravascular coagulation
 
• signs/symptoms within “minutes” of 
MSC infusion  • Stop the MSC infusion  
• Culture the recipi[INVESTIGATOR_841]’s blood and the MSC product.
 
• Immediately start broad spectrum antibiotics. The usual default should be vancomycin, 
meropenem or imipenim, and tobramycin.
 
• Use hemodynamic support as appropriate 
(IV fluids +/ - vasopressors).  
• Notify the BMT laboratory clinical scientists of the suspi[INVESTIGATOR_348032].
 
   
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 71  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix I: Mini -Bronchoalveolar Lavage Procedure  
 
Appendix I.  Mini-Bronchoalveolar Lavage Procedure  
 
The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimen s are 
obtained with the CombicathTM (Plastimed) catheter that is commonly used for the diagnosis  
of ventilator-associated pneumonia. The catheter is introduced from its protective sheath into the 
endotracheal tube through a standard bronchoscopy adapter, and then gently advanced into the lungs until it becomes wedged in a distal airway. The catheter then is withdrawn approximately [ADDRESS_432442]. This is 
accomplished by [CONTACT_348107]. Then, two 30-mL syringes containing 20 mL normal saline and a 5mL air bolus are injected rapi[INVESTIGATOR_348033]. Once the air bolus clears the second syringe, gentle aspi[INVESTIGATOR_348034] 10 s econds to retrieve as much of the instilled fluid as  
possible (usually 5-10 ml). When completed, the catheter is removed from the endotracheal tube. 
The recovered aspi[INVESTIGATOR_348035] a standard screw -top specimen container 
used for BAL samples. If the clinical condition warrants it, 1 ml can be deposited into a sterile  
container to be sent to the microbiology laboratory for culture. 
 Note: The mini- BAL procedure can be done with either one or two clinicians but it is easier to do (and typi[INVESTIGATOR_348036]) when two clinicians are involved: one to advance,  wedge, and 
manipulate the Combicath and the other to instill and aspi[INVESTIGATOR_348037]. The patient should be pre-oxygenated on an FiO
[ADDRESS_432443] to remove sputum from the airways.   After the mini- BAL, routine suction should be repeated to remove any excess BAL fluid that may be present in the airways. Assess patient’s oxygenation and ventilatory status and return patient to their baseline FiO
2 when clinically indicated, usually within 5-10 minutes. The 
ventilator circuit should be returned to its original configuration by [CONTACT_348108] a clean adapter that was originally present in the circuit. 
 
The mini -BAL should NOT be performed under the following circumstances:  
1. FiO
2 greater than 0.70 AND PEEP greater than 14 cm H 2O 
2. Hemodynamic instability (despi[INVESTIGATOR_348038]/pressor support)  
3. Open external ventricular device or intracranial pressure greater than 15mmHg or  unstable 
4. Most recent INR greater than 2.0 or PTT > [ADDRESS_432444] recent Platelets less than 50x103/mm3 (within 36 hours of BAL) 
 
Since this is a study procedure, any associated adverse event should be reported as a study  
related event. Transient hypoxemia is considered an expected event for ARDS, but prolonged or 
severe hypoxemia following mini- BAL should be reported as an adverse event.
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 72  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 Appendix J: Phase [ADDRESS_432445] Infusion Protocol  
 
BACKGROUND:  Human mesenchymal stem cells (hMSCs) are being tested in a placebo -
controlled trial as a novel therapy for the acute respi[INVESTIGATOR_1505]. Several factors are 
essential to the safe administration of hMSCs . They include accurate identification of the donor, 
the recipi[INVESTIGATOR_841]; the product; and the cell dose. Therapi[INVESTIGATOR_348039]. In addition, recognition and management of the potential side effects associated with hMSC infusion ar e also important.  Toxicity from DMSO used to protect hMSCs during 
cryopreservation is not a major concern since the hMSCs will be washed after the thaw and prior to infusion; renal toxicity from red blood cell disruption during the freeze/thaw procedure is  also 
not a concern since these cells are cultured prior to cryopreservation.  Each study site will develop its own site -specific Standard Operating Procedure in support of this 
protocol. The site -specific standard operating procedure will be reviewed by t he Coordinating 
Center prior to initiating the clinical trial at that site.
 
 
 
1.  OBJECTIVE S 
1.1 To ensure the safe and effective infusion of  either clinical grade allogeneic bone marrow -
derived human mesenchymal stem cells (hMSCs)  or Plasmalyte A placebo.  
1.2 To ensure the administration of the full hMSC dose  (10 million cells/kg predicted body 
weight).  
1.[ADDRESS_432446] being infused (hMSCs or placebo). 
 
 
2. MATERIALS/EQUIPMENT  
2.1 250mL Normal Saline bag (delivered by [CONTACT_348109]) 
2.[ADDRESS_432447] blood filter tubing Y set (170- 260 micron filter): At UCSF Medical Center, this is 
Baxter 4C6772 (delivered by [CONTACT_348109]) 
2.[ADDRESS_432448] bag (delivered by [CONTACT_348109]) 
2.4 Semi-opaque tubing sleeve to cover tubing (delivered by [CONTACT_348109]) 
2.5 Gloves (in ICU)  
2.[ADDRESS_432449] luer stopcock  (in ICU) 
2.7 10mL luer- lock syringe (in ICU)  
 
 3. POLICIES  
3.[ADDRESS_432450] bag by [CONTACT_348110]  (BMT) laboratory staff. This 
time will be [ADDRESS_432451] expi[INVESTIGATOR_348040]. Infusion 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 73  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 Appendix J: Phase [ADDRESS_432452] to the BMT laboratory immediately.  
3.5 No prophylactic pre -medications (e.g. acetaminophen or diphenhydramine) will be 
administered prior to the investigational pr oduct infusion.  If such medications are ordered 
by [CONTACT_348111], however, their use does not 
preclude proceeding with the infusion. 
3.6 The following medications should be immediately available at the patient’s b edside during 
the infusion and the post -infusion monitoring period: epi[INVESTIGATOR_238] [ADDRESS_432453]  infusion. The  
infusion should not be  “pi[INVESTIGATOR_348017]” into a medication line. If absolutely necessary, a 
stopcock can be used at the lumen connection to create a separate, dedicated line for the investigational product  infusion. Avoid administration with dextrose containing solutions; 
Normal saline, Plasmalyte, and Lactated Ringers are acceptable.  
3.9 Dialysis Patients:  Patients receiving intermittent dialysis may be dialyzed prior to the 
investigational product  infusion, but should not be dialyzed until 24 hours or more after 
receiving the infusion if possible. Continuous renal replacement therapy will be allowed to 
continue during the hMSC or placebo infusion. 
3.10 Prone positioning: Patients must remain in the supi[INVESTIGATOR_348041]-infusion observation period. 
3.[ADDRESS_432454] precautions and aseptic technique at all times.  
3.12 Verify patient’s identity per National Patient Safety Goals (two identifiers). (At UCSF Medical Center, the Department of Nursing Blood and Blood Components Admini stration 
Procedure should be followed). 
3.[ADDRESS_432455] infusion during 
administration (see Appendix H for potential side effects  and symptom management 
guidelines ). 
  4. PROCEDURE  
4.[ADDRESS_432456] will be thawed, processed, or released from the BMT laboratory without this order.  
(At UCSF Medical Center: Fax infusion order to BMT  Lab, fax #353- 1227.  Confirm 
infusion time with BMT laboratory at 353-1789). 
4.2 Personnel from the BMT lab will s et up IV tubing as follows: 250mL normal saline bag  
spi[INVESTIGATOR_348042] “Y-set” standard blood filter tubing (170 - 260 micron filter 
tubing, for example Baxter 4C6772). The BMT lab will s aline prime the blood filter tubing 
setup. The IV tubing will be covered with the blinding sleeve. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 74  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 Appendix J: Phase [ADDRESS_432457]  will be admin istered as 100 mL in a 300 mL transfer bag; this 
bag will be covered with an opaque bag  to blind investigators to the content. The BMT 
laboratory will label both the transfer bag and the blinding bag with the patient identifiers , 
then spi[INVESTIGATOR_348043]-primed IV tubing. 
4.4 The Study Physician will: 
• Confirm that the patient has met criteria to receive the investigational product  
infusion: in addition to meeting inclusion criteria and having no exclusion criteria, the 
[ADDRESS_432458]  been achieved, and the PaO2/FiO2 ratio on a 
blood gas obtained during the last 30 minutes of the stable baseline prior to infusion 
cannot exceed 300. If the PaO2/FiO2 ratio is greater than 300, the patient is no longer 
eligible to receive the investigational product. 
• Follow National Patient Safety Goals to identify the patient (two identifiers).   (At 
UCSF Medical Center: Verify patient identification per Department of Nursing Blood and Blood Components Administration Procedur e). 
• Verify that the signed consent is in the patient’s medical record.  
• Review the infusion order. 
• BMT lab personnel will review the  information on the investigational product  bag 
with the bedside RN or study physician for the following:   
• Recipi[INVESTIGATOR_285219]/ID#  
• Recipi[INVESTIGATOR_348021]  
• Product expi[INVESTIGATOR_320]/time  
One person should read the information on the product and a second person should compare it with the information on the paperwork and patient identification band. One of these two individuals should be a study investigator.  
• Prior to infusion, the study physician should ensure that the following medications are 
available at the patient’s bedside:  
• Epi[INVESTIGATOR_238]: 1 mg 
• Hydrocortisone: 100 mg 
• Benadryl: 50 mg 
4.5 The study physician will be present for the entire infusion procedure: 
• The investigational product bag will arrive from the BMT lab already spi[INVESTIGATOR_348044] -primed tubing, and covered with the semi- opaque sleeve.  
o The investigational product  can be infused immediately after the product arrives at the 
bedside from the BMT laboratory and all patient checks have been completed. There is 
no need to wait for the bag to come to room temperature.  
• The study physician will attach  the primed filter tubing to a three-way stopcock and the 
intravenous line through which the investigational product is to be infused. 
o Do NOT use bifuse tubing. DO NOT INFUSE THROUGH A NEEDLELESS CAP.  
• The study physician will c onfirm that all IV connections are secure and that the infusion 
lines from the investigational product bag  to the patient are visible  but covered with the 
semi-opaque sleeve.  
• Document the start date and time of the investigational product  infusion on the START 
Infusion Record. 
• If there is accidental unblinding, contact [CONTACT_348112]-call to discuss how to 
proceed. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 75  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 Appendix J: Phase [ADDRESS_432459] Infusion Protocol  
 
4.6 Start the infusion: 
• At each center, the priming volume of the filter set must be measured prior to enrollment of 
the first study patient:  
o For example, for Baxter 4C6772, the priming volume ranges from 80- 100 mL, 
depending on the drip chamber prime volume 
o The drip chamber should not be primed to “full” since the infusion rate will be set 
based on the number of drops/minute that are us ed 
o The clamps CAN be opened and closed through the blinding tubing. If you are having difficulty opening and closing the clamps, however, you can cut a small vertical hole in the sleeve to allow direct access to the clamp.  
• Run HALF of the estimated priming  volume in over 10- 15 minutes, checking the drop rate 
at the start of the infusion and approximately 5 minutes later. These can be visualized 
through the semi -opaque tubing sleeve. The drop rate should be checked by [CONTACT_348113] 30 seconds and calculating the number of drops/minute. 
• Run the remain HALF of the estimated priming volume and the investigational product  in 
over 50-60 minutes, checking the drop rate at the start of the infusion, approximately 5 
minutes after the start, and pe riodically throughout the infusion 
• For the Baxter 4C6772 filter set: 
o Infuse 40 mL over 10- 15 minutes, calculating the drop rate/minute   
 The # drops/mL for this priming set per the manufacturer is approximately 15 
 Therefore 40 mL = 40 mL * 15 drop/mL = 600 drops 
 600 drops/10 minutes = 60 drops/minute = 30 drops/30 seconds 
 600 drops/15 minutes = 40 drops/minute = 20 drops/30 seconds 
 Therefore the target infusion rate is 25-30 drops/[ADDRESS_432460], 
 (40 mL prime + [ADDRESS_432461]) * 15 drops/mL = 2100 drops 
 2100 drops/50 minutes = 42 drops/minute = 21 drops/30 seconds  
 2100 drops/60 minutes = 35 drops/minute = 17.5 drops/30 seconds  
 Therefore the target infusion rate is 18 -20 drops/[ADDRESS_432462]  bag is empty, proceed to the RINSE AND FLUSH 
PROCEDURES  (4.12) to rinse the bag and flush the line.  
4.[ADDRESS_432463]  
through line slowly (2- 5 mL/min) via a syringe.  
4.[ADDRESS_432464] original filter set for the bone marrow transplant laboratory; they should visually examine the filter set for clumpi[INVESTIGATOR_348045] . If clumpi[INVESTIGATOR_348046], contact [CONTACT_348114].  
4.11 Monitoring:  
• Blood pressure, heart rate and oxygen saturation will be continuously monitored for the 
duration of the infusion and documented every 15 minutes during the infusion. 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 76  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
 Appendix J: Phase [ADDRESS_432465] Infusion Protocol  
 
• An arterial blood gas will be obtained within the 30 minutes prior to the start of the 
infusion (DURING the baseline stability period) and within 15 minutes  of the end of the 
infusion. If the paO2/FiO2 ratio on the blood gas obtained during the baseline stability 
period is greater than 300, the patient should NOT receive the investigational product. 
• See Appendix H for potential side effects of the infusion. Monitor periodically during the 
infusion for these side effects.  If the patient experiences significant side effects, consider pausing or stoppi[INVESTIGATOR_348025]. 
4.12 RINSE AND FLUSH PROCEDURE: Approximately [ADDRESS_432466] ha s been rinsed from the bag and infused through the priming setup. 
The target infusion rate during the rinse and flush procedure is increased, as the patient has already re ceived a large portion of the infusion, and the rinse is expected 
to be more dilute.  
• At the end of the infusion, rinse the investigational product  bag with normal saline using 
this protocol. To do this: (1) Clamp the investigational product  line to the patient (2) 
Unclamp the saline line and lower the investigational product  bag to allow for saline to 
enter the investigational product  bag; (3) After a small amount of saline (approximately 20 
mL) has entered the investigational product  bag, reclamp the saline line; (4) Swirl the 
saline in the investigational product  bag; (5) Re-hang the investigational product  bag, then 
open the line and infuse the saline rinse from the investigational product  bag into the 
patient until the bag is empty; (6) F inally, allow 80 mL (priming volume) of saline to run 
through the filter to flush the remaining rinse volume into the patient.  The rinse and flush 
volume should be infused over 20 minutes:  
 (20 mL rinse + 80 mL flush) * 15 drops/mL = 1500 drops 
 1500 drops/20 minutes = 75 drops/minute = 32.5 drops/30 seconds  
 Therefore the target infusion rate for the rinse and flush is approximately 30 drops/[ADDRESS_432467] bags and tubing should be returned to the BMT laboratory 
4.14 Obtain and document vital signs at completion of infusion. 
 
5. Documentation:  
5.[ADDRESS_432468] should be placed in the patient’s paper medical record or scanned into the electronic medical record; a hard copy must also be sent 
to the local BMT lab and to the University of Minnesota. 
5.2 The study investigator will confirm with  the bedside RN the total volume ( investigational 
product and saline wash) used during the infusion procedure so this can be documented in 
the patient’s medical record.  
5.[ADDRESS_432469] and any compli cations or adverse 
reactions.  
 
 
Date:  February 17, 2015  Confidential    
Michael A Matthay, MD   Page 77  
University of [LOCATION_004], San Francisco   Clinical Study Protocol UCSF -hMSC -ARDS- P1P2 -06 
  Appendix K: Barotrauma 
 
Appendix K. Barotrauma  
 
Evidence of barotrauma includes the following: 
• Pneumothorax 
• Bronchopleural fistula 
• Tracheobronchial fistula  
• Pneumomediastinum 
• Subcutaneous emphysema 
• Pneumoatocoele 
       
 
   
Date:  February 17, 2015  Confidential                                                          